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The group IVA cytosolic phospholipase A2 (cPLA2α or PLA2G4A) 
contributes to chronic neurodegeneration via the generation of arachidonic 
acid and proinflammatory eicosanoids. While much is known about regulation 
of cPLA2 by post-translational modifications such as phosphorylation, little is 
known about its epigenetic regulation. In the first part of the study, treatments 
with histone deacetylase (HDAC) inhibitors trichostatin A (TSA), valproic acid 
(VPA), tubacin and especially the class I HDAC inhibitor, MS-275, were found 
to increase cPLA2α mRNA expression in SH-SY5Y human neuroblastoma 
cells. Co-treatment of the histone acetyltransferase (HAT) inhibitor, anacardic 
acid, modulated upregulation of cPLA2α induced by TSA. Specific involvement 
of class I HDACs and the Tip60 HAT in cPLA2α regulation was further shown, 
where a Tip60-specific HAT inhibitor, NU9056, modulated the upregulation of 
cPLA2α induced by MS-275. In addition, co-treatment of the histone 
methyltransferase (HMT) inhibitor, 5’-deoxy-5’-methylthioadenosine (MTA), 
with TSA suppressed TSA-induced cPLA2α upregulation. The above changes 
in cPLA2α mRNA expression were corroborated at the protein level by 
Western blots and immunocytochemistry. Chromatin immunoprecipitation 
(ChIP) showed that TSA increased binding of trimethylated H3K4 to the 
proximal promoter region of the cPLA2α gene. Cell injury after TSA treatment 
as indicated by lactate dehydrogenase (LDH) release was modulated by 
anacardic acid, and a role of cPLA2 in mediating TSA-induced injury was 
shown after co-incubation with the cPLA2 selective inhibitor, arachidonyl 




suppression of TSA-induced cPLA2α expression was observed after co-
incubation of cells with leaf extracts of Clinacanthus nutans Lindau (C. 
nutans), commonly referred to as ‘Sabah Snake Grass’, with TSA. HAT 
inhibitory properties of C. nutans were detected via HAT activity assay. Similar 
to anacardic acid, C. nutans also abrogated TSA-induced cell injury, indicating 
its cytoprotective potential. Together, these findings provide hope for 
epigenetic regulation of cPLA2, and the potential of phytochemicals to affect 
this process, to be a potential target for therapy for chronic inflammation. 
   
  
List of Tables 
 
 XII 









Table 1.3 Summary of clinical, pathological and anatomical 





HDAC, HAT and HMT inhibitor activites and 




Table 3.1.5 Types of histone lysine modifications 30 
  
List of Figures 
 
 XIII 






Figure 1.6 Diagram showing involvement of PLA2 isoforms in 
mediating neural injury 
 
10 
Figure 2.0 Illustration of different modes of action of 




Figure 2.3.1 Illustration of cPLA2 crystal structure 
 
16 
Figure 3.1 Effect of HDACs, HATs, and respective inhibitors on 
regulation of chromatin conformation 
 
20 
Figure 3.1.5 Illustration of three types of histone modifications, 
namely phosphorylation (white), acetylation (red) 
and methylation (yellow) that occur on specific 






Figure 1.3.1.1  Real-time RT-PCR analyses of (A) cPLA2α and (B) 
iPLA2ß mRNA expression after dose-dependent 




Figure 1.3.1.2 Real-time RT-PCR analyses of (A) cPLA2α and (B) 
iPLA2ß mRNA expression after dose-dependent 




Figure 1.3.1.3 Real-time RT-PCR analyses of (A) cPLA2α, (B) 
iPLA2ß mRNA expression after dose-dependent 
treatment with HDAC6-specific inhibitor, tubacin 
 
62 
Figure 1.3.1.4 Real-time RT-PCR analyses of (A) cPLA2α, (B) 
iPLA2ß mRNA expression after dose-dependent 
treatment with class I HDAC inhibitor, MS-275 
 
63 
Figure 1.3.2.1 Real-time RT-PCR analyses of (A) cPLA2α and (B) 
iPLA2ß mRNA expression after dose-dependent 




List of Figures 
 
 XIV 
Figure 1.3.2.2 Real-time RT-PCR analyses of (A) cPLA2α, (B) 
iPLA2ß mRNA expression after dose-dependent 




Figure 1.3.3.1 Effect of general HAT inhibitor, anacardic acid (AA), 
and general HDAC inhibitor, TSA treatment 
 
67 
Figure 1.3.3.2 Real-time RT-PCR analyses of cPLA2α mRNA 




Figure 1.3.3.3 Effect of Tip60-specific HAT inhibitor NU9056 and 
class I-specific HDAC inhibitor, MS-275 treatment 
 
71 
Figure 1.3.4 Effect of HMT inhibitor MTA and general HDAC 
inhibitor, TSA on cPLA2 expression 
 
75 
Figure 1.3.5.1 Shearing efficiency of DMSO control and TSA-
treated chromatin analysed on 1.5% agarose gel 
 
78 
Figure 1.3.5.2 University of California Santa Cruz (UCSC) genome 
browser screenshots and loci of primer design. 
 
79 
Figure 1.3.5.3 Chromatin immunoprecipitation (ChIP) assay 
results. Fold enrichment of human cPLA2 gene 
region (+143 to +349) after immunoprecipitation with 
(A) anti-H3K9 acetylated (H3K9ac) and (B) anti-
H3K4 trimethylated (H3K4me3) antibodies 
 
80 
Figure 1.3.6 Percentage of acetylated H3K9 residues detected in 









Figure 2.3.1 Real-time RT-PCR analyses of cPLA2α mRNA 
expression after treatment with C. nutans and 
general HDAC inhibitor, TSA 
 
102 
Figure 2.3.2 Histone acetyltransferase (HAT) activity assay 
results showing HAT activity in arbitrary 
fluorescence units (AFU) 
 
103 
Figure 2.3.3 Percentage of acetylated H3K9 residues detected in 
cells, compared to untreated controls 
 
104 
Figure 2.3.4 Effect of C. nutans and general HDAC inhibitor, TSA 105 
List of Figures 
 
 XV 
treatment on cPLA2 protein expression 
 
Figure 2.3.5 Trypan blue exclusion assay results 
 
107 





List of Abbreviations 
 
 XVI 
LIST OF ABBREVIATIONS 
AA  Anacardic acid 
AACOCF3 Arachidonyl trifluoromethyl ketone 
AD  Alzheimer’s disease 
AFU  Arbitrary fluorescence units 
ALS  Amyotrophic lateral sclerosis 
ANOVA Analysis of variance 
APP  Amyloid precursor protein 
ATCC  American type culture collection 
ATP  Adenosine triphosphate 
BSA  Bovine-serum albumin 
CCM  Curcumin 
cDNA  Complementary DNA 
ChIP  Chromatin immunoprecipitation 
CNS  Central nervous system 
COX  Cyclooxygenase 
cPLA2  Cytosolic phospholipase A2 
DALY  Disability-adjusted life year 
DHA  Docosahexanoic acid  
DMEM Dulbecco’s modified eagle’s medium 
DMSO Dimethyl sulfoxide 
EGCG Epigallocatechin-3-gallate 
FBS  Fetal bovine serum 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
List of Abbreviations 
 
 XVII 
IL-6  Interleukin-6 
IL-8  Interleukin-8 
IL-1α  Interleukin-1-alpha 
IL-1ß  Interleukin-1-beta 
LDH  Lactate dehydrogenase 
LOX  Lipoxygenase 
Lp-PLA2 Lipoprotein-associated phospholipase A2 
LSD1  Lysine specific demethylase 1 
LTP  Long-term potentiation 
HAT  Histone acetyltransferase 
HD  Huntington’s disease 
HDAC  Histone deacetylase 
HKMT  Histone lysine methyltransferase 
HMT  Histone methyltransferase 
iPLA2  Calcium-independent phospholipase A2 
MTA  5’-deoxy-5’-methylthioadenosine 
NF-kB  Nuclear factor-kappa B 
NSAIDs Non-steroidal anti-inflammatory drugs 
PAF  Platelet activating factor 
PBS  Phosphate buffered saline 
PD  Parkinson’s disease 
PLA2  Phospholipase A2 
PKC  Protein kinase C 
PRMT  Protein arginine methyltransferase 
List of Abbreviations 
 
 XVIII 
PS1  Presenilin 1 
PS2  Presenilin 2 
RIPA  Radioimmunoprecipitation assay 
ROS  Reactive oxygen species 
SAHA  Suberoylanilide hydroxamic acid 
SIRT  Sirtuin 
sPLA2  Secretory phosholipase A2 
SRE  Sterol regulatory element 
SREBP Sterol regulatory element binding protein 
TBST  Tris-buffered saline with 0.1% Tween-20 
TNFα  Tumor necrosis factor-alpha 
TSA  Trichostatin A 
TSS  Transcriptional start site 








Various parts of this study have been published in international 
refereed journals:  
1. Tan Charlene SH, Ong WY (2015). Epigenetic regulation of 
cytosolic phospholipase A2 in SH-SY5Y human neuroblastoma 


















1.1 Epidemiology  
 ‘Neurodegeneration’ is a broad term referring to “any 
pathological condition primarily affecting neurons” (Przedborski et al., 
2003). A few hundred types of neurodegenerative diseases exist, 
classified based on their clinical features and areas of lesion 
(Przedborski et al., 2003). Neurodegeneration is one of the leading 
contributors to disease burden worldwide, affecting both developing 
and developed countries (Kalaria et al., 2008, Lee, 2009). Global 
health estimates reveal Alzheimer’s disease (AD) as the most 
prevalent neurological disease, followed by Parkinson’s disease (PD) 
and multiple sclerosis (WHO, 2012). According to the Global Health 
Education Consortium (Lee, 2009), global neurological disease burden 
is projected to increase 12% from 2005 to 2030, with a 62% increase in 
disability-adjusted life years (DALYs1) for neurodegenerative diseases, 
in contrast to a 20% increase in DALYs for cerebrovascular diseases 
(WHO, 2006). An estimated figure of up to 16 million Americans and 
115.4 million individuals worldwide will suffer from AD by 2050 (Hebert 
et al., 2003, International, 2010). In Singapore, this figure is expected 
to hit 187,000, which contributes approximately 5% of the total 
population (Economics, 2006). There is thus a growing need for 
effective mitigation of these debilitating diseases. 
 
                                            
1 Disability-adjusted life year: “a measure of overall disease burden, expressed as the 





1.2 Acute and chronic neurodegeneration 
 Neurodegenerative disorders are broadly classified as acute and 
chronic neurodegeneration (Allan and Rothwell, 2001). Acute 
neurodegeneration occurs promptly after a sudden insult and lasts for a 
short period, usually leading to rapid cell damage and death (Allan and 
Rothwell, 2001). Examples of acute neurodegeneration are stroke, 
cerebral or subarachnoid haemorrhage, ischaemic brain damage and 
traumatic brain injury (Allan and Rothwell, 2001).  
 Chronic neurodegeneration occurs when the unfavorable 
stimulus persists even after the initial insult and lasts for a prolonged 
period of time (Frank-Cannon et al., 2009). Examples of chronic 
neurodegeneration are AD, PD, amyotrophic lateral sclerosis (ALS), 
multiple sclerosis and Huntington’s disease (HD) (Streit et al., 2004, 
Lull and Block, 2010). 
 
1.3 Hallmarks of neurodegeneration 
 Various types of neurodegeneration differ according to their 
pathological hallmarks. Acute forms of neurodegeneration such as 
stroke are characterized by cell death due to injury or ischemia (Allan 
and Rothwell, 2001). Chronic forms of neurodegeneration are typically 
classified by their mode of transmission, type of protein accumulation, 
and brain regions affected (Table 1.3). For instance, general 
pathological hallmarks of AD include deposition of amyloid plaques and 





promote oxidative stress and neuronal death (Hsieh and Yang, 2013). 
Lewy bodies containing α-synuclein protein give rise to inflammation 
and neurotoxicity in PD (Kang et al., 2013). A summary of common 
neurodegenerative diseases and their corresponding clinical, 
pathological and anatomical hallmarks are presented in Table 1.3. 
 
Table 1.3 Summary of clinical, pathological and anatomical hallmarks 








































Huntingtin Cerebral cortex, 
striatum 
 
1.4 Etiology of neurodegeneration 
 Genetic and environmental factors promote the onset of the 
above-mentioned pathological hallmarks. Typical genetic factors 
responsible for familial or early-onset AD are genes encoding amyloid 
precursor protein (APP) (Goate et al., 1991), presenilin 1 (PS1) 
(Sherrington et al., 1995) and presenilin 2 (PS2) (Rogaev et al., 1995). 
However, these familial cases make up a small proportion (~10%) of all 





inherited (Tanner et al., 1999). Dysfunctions to the central nervous 
system (CNS) accumulate progressively over time and the disease only 
manifests later in life (Ritchie and Kildea, 1995). For instance, 
APP/PS1 mutant mice showed early dysfunctions in working memory, 
but amyloid burden and long-term memory loss only occurred later, 
indicating progressive development of the disease (Trinchese et al., 
2004). Environmental factors contribute to sporadic cases of chronic 
neurodegeneration (Migliore and Coppedè, 2009), such as where diet-
induced obesity induces accumulation of proinflammatory factors in the 
brain and leads to cognitive impairment (Miller and Spencer, 2014). 
Excessive iron accumulation with age increases tissue damage to the 
hippocampus and contributes to AD pathology (Grant et al., 2002, 
Raven et al., 2013). In contrast, moderate exercise provides anti-
inflammatory and memory-enhancing effects (Cotman et al., 2007). 
Changes in expression of certain genes related to chronic 
inflammation, calcium binding and protein synthesis are also implicated 
in AD (Loring et al., 2001). It seems therefore that both environmental 
factors and gene expression changes contribute to the etiology of late-
onset and sporadic neurodegeneration. 
Actual mechanisms behind neurodegeneration remain highly 
debated. Currently, opposing schools of thought argue the relative 
importance of amyloid plaques and tau protein in AD (Rapoport et al., 
2002, Morris et al., 2010). Much controversy exists concerning whether 





stages of the disease (Skaper, 2012). Still others believe that tau 
protein, rather than amyloid burden, correlates much better to severity 
of cognitive decline (Nelson et al., 2012). Furthermore, while it is 
traditionally thought that the tau protein occurs only in AD, and α-
synuclein only in PD, recent studies show presence of the tau protein 
in PD cases (Herbert et al., 2014) and Lewy bodies in AD cases 
(Koehler et al., 2013). Therefore, much research is necessary for a 
clearer mechanistic understanding of the etiology of 
neurodegeneration. 
Chronic inflammation and oxidative stress are commonly 
observed in neurodegenerative diseases; namely, in AD, PD, ALS and 
HD (Khansari et al., 2009, Hensley, 2010, Moller, 2010, Philips and 
Robberecht, 2011, Hirsch et al., 2012). The process involves microglial 
activation and production of proinflammatory mediators such as 
prostaglandins, nitric oxide, or cytokines that promote neuronal death 
(Hsieh and Yang, 2013). Microglial activity is implicated alongside tau 
and amyloid pathologies in neurons (Kitazawa et al., 2004), as shown 
by co-localisation of activated microglia, amyloid plaques and tau 
protein found in the neurons of brains of AD patients (Cagnin et al., 
2001, Ishizawa and Dickson, 2001). Proinflammatory proteins such as 
C-reactive protein and interleukin-6 (IL-6) in the plasma of patients also 
correlate with increased risk of AD, pointing to the presence of 
inflammation in AD (Engelhart et al., 2004). Furthermore, non-steroidal 





suppressing ß-amyloid formation (Vlad et al., 2008). Taken together, 
accumulating evidences suggest inflammation as a common 
characteristic of chronic neurodegenerative diseases. 
 
1.5 Neuroinflammation 
The term ‘neuroinflammation’ has been coined in recent years to 
describe features and pathological hallmarks present in most 
neurodegenerative disorders (O'Callaghan et al., 2008). 
Neuroinflammation is a form of inflammation unique to the CNS, 
characterised by activation of immune cells in the brain known as glia 
that release proinflammatory mediators (O'Callaghan et al., 2008). 
Outside of the CNS, such immune cells are known as monocytes, 
macrophages and neutrophils (O'Callaghan et al., 2008). Under normal 
conditions, inflammation in the CNS plays a neuroprotective role by 
aiding in clearance of foreign invaders and healing from external injury 
(Cappellano et al., 2013). Microglia and astroglia serve as trophic 
factors to facilitate neuronal repair, development and plasticity (Ridet et 
al., 1997, Bauer et al., 2007). They also maintain homeostasis by 
providing immune response to external stress and neurotoxic insults 
(Yang et al., 2010). This step is necessary for activation of the immune 
system to promote killing of foreign invaders (Lucas et al., 2010, 
Soehnlein and Lindbom, 2010). Under controlled conditions where the 
blood brain barrier is intact and leukocytes do not infiltrate, glial activity 





recovery from injury (Streit et al., 2004). Inflammatory response shifts 
to an anti-inflammatory state to rescue damaged areas and facilitate 
clearance of debris from neurons (Varin and Gordon, 2009). 
Under conditions where the proinflammatory response persists, 
excessive release of proinflammatory cytokines and reactive oxygen 
species (ROS) cause further tissue damage and neurodegeneration 
(Kigerl et al., 2009, Cappellano et al., 2013). These effects are evident 
in acute brain injuries such as stroke, traumatic brain injury and spinal 
cord injury (Allan and Rothwell, 2001, Patel et al., 2003, Jafarian-
Tehrani, 2009). Acute neuroinflammation is generally characterized by 
microglial activation and overexpression of proinflammatory cytokines 
such as interleukin 1-alpha (IL-1α), interleukin 1-beta (IL-1ß), IL-6 and 
tumor necrosis factor-alpha (TNF-α) (Czerniawski and Guzowski, 
2014). 
Acute neuroinflammation can give rise to long-term chronic 
neuroinflammation, such as the long-term inflammatory effects 
observed after severe traumatic brain injury (Lozano et al., 2015). 
Chronic neuroinflammation plays a significant role in the study of CNS 
disease, as opposed to acute forms of neuroinflammation that 
generally play a role in CNS injury. In such cases, neuroinflammatory 
processes were reported to have begun long before neuronal death is 
observed, accelerating or exacerbating disease progression (Shivika et 
al., 2014). The term ‘neuroinflammation’ is thus more commonly 





excessive and prolonged glial activation leads to overproduction of 
proinflammatory cytokines and reactive oxygen species, causing 
neuronal degradation over time (Streit et al., 2004, O'Callaghan et al., 
2008, Yang et al., 2010).  
 
1.6 Role of cPLA2 in neuroinflammation and neurodegeneration 
 Calcium-dependent cytosolic phospholipase A2 (cPLA2) 
catalyses the release of arachidonic acid from the cleavage of 
membrane glycerophospholipids, which contributes significantly to 
neuroinflammation and disease, and this is termed, the “Bazan effect” 
(Bazán Jr, 1970). Increased cPLA2 expression is found in cases of 
human AD, in mice models of ALS, in mice overexpressing mutant 
APP, as well as in mice with age-related amyloid deposition (Clemens 
et al., 1996). Elevated cPLA2α immunoreactivity occurs together with 
amyloid deposits in cortical and hippocampal neurons of AD patients 
(Stephenson et al., 1996, Desbene et al., 2012). Increased cPLA2 
immunoreactivity is also found in neuronal cultures during ischemic and 
excitotoxic insults (Bonventre, 1997), and in neurons of rat brains 
following kainic-acid induced neurotoxicity (Sandhya et al., 1998, 
Farooqui et al., 2000). These indicate the crucial role of cPLA2 in 
neurodegeneration. 
 Oxidative stress and inflammation increases cPLA2 expression 
in neurons and microglia (Sun et al., 2004, Sun et al., 2012). cPLA2 





isoprostanes and the neurotoxic 4-hydroxynonenal from the catalysis of 
neural membrane phospholipids, leading to neurodegeneration (Ong et 
al., 2010). Figure 1.5 illustrates the different roles of PLA2 in modulating 
normal brain functions and preventing neural injury (Ong et al., 2010). 
The cPLA2 isoform is most responsible for neurodegeneration, while 
the calcium-independent PLA2 (iPLA2) isoform plays a more significant 




Fig. 1.6 Diagram showing involvement of PLA2 isoforms in 
mediating neural injury. PlsEtn-PLA2: plasmalogen selective 
phospholipase A2; A1, A2, A3: Agonist A1, Agonist A2, Agonist A3 
respectively; PtdCho: phosphatidylcholine; PlsEtn: ethanolamine 
plasmalogen; lyso-PtdCho: lysophosphatidylcholine; lyso-PlsEtn: 
lysoplasmalogen; FFA: free fatty acid; ARA: arachidonic acid; DHA: 
docosahexaenoic acid; 4-HNE: 4-hydroxynonenal. [Adapted from (Ong 
et al., 2010)] 
 
 In support of this, loss-of-function studies show that specific 
inhibition of cPLA2 by arachidonyl trifluoromethyl ketone (AACOCF3) 





cPLA2-knockout mice conferred resistance to Aβ-induced cognitive 
deficits and synaptic loss (Desbene et al., 2012). Antisense knockdown 
of cPLA2 protected rat cortical neurons from Aβ-induced apoptosis by 
inhibiting downstream arachidonic acid-dependent pathways (Kriem et 
al., 2005). Together, these findings show the crucial involvement of 
cPLA2 activity in neuroinflammation and neurodegeneration, and thus 
its need to be tightly regulated. 
 
2.0 Phospholipases A2 
The phospholipase A2 (PLA2) superfamily of enzymes are 
enzymes found ubiquitously in most cells and tissues, catalyzing the 
hydrolysis of cellular phospholipids at the sn-2 position to release free 
fatty acids and lysophospholipids (Murakami et al., 1997, Winstead et 
al., 2000).   
 
Fig. 2.0 Illustration of different modes of action of 
phospholipases A1, A2, C and D, at different cleavage sites. PLA2 
cleaves phospholipids at sn-2 position, releasing a free fatty acid and 





At least 19 isoforms of PLA2 enzymes exist to date, differing in 
terms of structure, substrate specificity, calcium dependence, and 
localisation (Winstead et al., 2000, Murakami and Kudo, 2002). Three 
main families of PLA2 include the secretory PLA2 (sPLA2), group VI 
calcium-independent PLA2 (iPLA2) and group IV calcium-dependent 
cytosolic PLA2 (cPLA2) (Murakami and Kudo, 2002). 
 
2.1 Secretory phospholipase A2 
  The secretory phospholipase A2 (sPLA2) gene is localised on the 
human chromosome 4q25 (Gelb et al., 2000). The sPLA2 family of 
proteins has low molecular weights ranging from 14 to 17 kDa, and 
calcium is necessary for its function (Murakami et al., 2011). They have 
homologous amino acid sequences and three-dimensional structures 
(Gelb et al., 2000, Valentin and Lambeau, 2000), with similar calcium-
binding domains and His/Asp cataytic sites maintained by disulfide 
bridges (Titsworth et al., 2008). There are at least ten isoforms of 
sPLA2 named based on the patterns of disulfide bonds and their time of 
discovery – IB, IIA, IIC, IID, IIE, IIF, III, V, X and XII (Burke and Dennis, 
2009a). Besides the catalytic domains and Ca2+-binding domains, the 
sPLA2-III and sPLA2-XII isoforms are poorly homologous against the 
sPLA2-I, -II, -V and -X subtypes (Murakami et al., 2011). Each sPLA2 
isoform produced has unique catalytic properties and localisation, thus 
they carry out unique pathophysiological roles in the mammalian 





expressed in the brainstem, spinal cord and neocortex of rats and is 
predominantly found in the cytosol of neuronal cells (Yang et al., 2013).  
 Some sPLA2 enzymes carry out similar functions as cPLA2, 
generating arachidonic acid and proinflammatory eicosanoids 
(Lambeau and Gelb, 2008). The sPLA2 releases arachidonic acid that 
plays important roles in neuroinflammation (Bazan, 2003, Serhan, 
2004), neurotransmission (Bramham et al., 1994) and long-term 
potentiation (Williams et al., 1989). 
 
2.2 Calcium-independent phospholipase A2 
The iPLA2 gene is localised on the human chromosome 22q13.1 
(Larsson Forsell et al., 1999). It contains a CpG island but lacks a 
TATA-box (Tanaka et al., 2012). It also has a putative sterol regulatory 
element (SRE) on the 5’ flanking region of the gene, allowing the 
binding of sterol regulatory element binding proteins (SREBPs) for 
transcriptional regulation (Seashols et al., 2004). Under situations of 
sterol depletion, SREBPs translocate into the nucleus to bind SREs, 
increasing iPLA2 expression (Seashols et al., 2004). On the other hand, 
sterol supplementation suppresses iPLA2 induction, suggesting that 
sterols regulate iPLA2 activity (Seashols et al., 2004). Alternative 
splicing of the iPLA2 mRNA generates various isoforms with distinct 
tissue localisation and functions (Larsson et al., 1998). The three 
common isoforms of iPLA2 are iPLA2α, iPLA2ß, and iPLA2γ (Tang et 





iPLA2, is more well-studied and further classified into various splice 
variants, namely group VIA-1, VIA-2, VIA-3, ankyrin-1 and ankyrin-2 
(Winstead et al., 2000).  
This family of enzymes functions independently of calcium and 
has molecular masses ranging from 80 to 88 kDa (Farooqui and 
Horrocks, 2007). It contains a unique lipase consensus sequence and 
eight N-terminal ankyrin repeats (Farooqui and Horrocks, 2006). It has 
no structural similarity with cPLA2 and is about five times more highly 
expressed (Kramer and Sharp, 1997, Ong et al., 2010). The iPLA2 
family is most abundant in the brain, highly expressed in the cytosol of 
the prefrontal cortex, striatum, hypothalamus and hippocampus of 
normal rats (Molloy et al., 1998, Ong et al., 2005). Dense 
immunolabeling of iPLA2 was observed in the cerebral cortex, septum, 
amygdala and striatum while relatively lighter staining was observed in 
the thalamus, hypothalamus and subthalamic nucleus of monkey 
brains (Ong et al., 2005).  
 iPLA2 is involved in the catalysis of membrane phospholipids to 
release docosahexanoic acid (DHA) (Balsinde et al., 1995, Strokin et 
al., 2003), which is anti-inflammatory and facilitates cell survival (Lukiw 
et al., 2005, Schwab et al., 2007). It is metabolized to docosanoids that 
have neuroprotective and neurotrophic properties (Marcheselli et al., 
2003). It reverses effects of oxidative damage in cellular membranes 
(McLean et al., 1993, Ross et al., 1998), facilitates neurite outgrowth 





(Schaeffer et al., 2009), and prevents ischemic damage (Strokin et al., 
2006). The iPLA2ß isoform plays a crucial role in hippocampo-
prefrontal cortical long-term potentiation (LTP) and spatial working 
memory in rats (Shalini et al., 2014). In line with these findings, AD 
patients were found to have deficient iPLA2 and DHA levels, but 
elevated levels of cPLA2 and arachidonic acid (Soderberg et al., 1991).  
 
2.3 Cytosolic phospholipase A2 
2.3.1 Structure and localisation 
The cPLA2α gene is localised on the human chromosome 1q25, 
comprising at least 7 introns with a CA repeat 160 bases upstream 
from the transcriptional start site (TSS) (Morii et al., 1994b, Tay et al., 
1994). The gene is expressed in numerous regions, but mRNA levels 
are most significant in the lung, kidney, spleen, heart and brain 
(Liscovitch, 1994). Several binding sites on the promoter regions are 
important for gene regulation (Cowan et al., 2004). These include the 
nuclear factor κB (NF-κB) binding site, glucocorticoid response 
element, interferon-γ-responsive element, interferon γ-activated 
sequence sites, and a distal regulatory sequence known as the 
hypoxia-inducible factor-1 binding site (Morii et al., 1994a, Wu et al., 
1999, Alexandrov et al., 2006). These sites allow the binding of 
transcription factors such as NF-kB, NF-IL6, AP-1 and AP-2 to regulate 





The cPLA2 family of enzymes is calcium-dependent and found 
intracellularly (Farooqui and Horrocks, 2007). It is an 85-kDa enzyme 
that possesses a unique C2 calcium-binding domain to facilitate 
translocation from the cytosol to the membrane, where it exerts its 
function (Kramer and Sharp, 1997, Malmberg et al., 2003). Both the 
catalytic α/β hydrolase domain and the C2 domain are necessary for 
appropriate functioning of the enzyme (Dessen et al., 1999, Hsu et al., 
2008). The lid region and CAP region are unique to cPLA2, and 
conformational change to the lid region is necessary for activation of 
the enzyme (Burke et al., 2008).  
 
Fig. 2.3.1 Illustration of cPLA2 crystal structure. Orange denotes 
the C2 Ca2+ ion-binding domain. Purple denotes Ca2+ ions. Green 
denotes catalytic domain with yellow cap region at and pink lid region. 
Red denotes the active site residues Serine-228, Aspartate-549 and 
Arginine-200. Dark blue denotes PIP2 binding site, while light blue 





Three isoforms of cPLA2 exist  – cPLA2α (85 kDa), cPLA2ß (114 
kDa) and cPLA2γ (61 kDa), where the function of cPLA2α is most 
studied. They possess conserved catalytic sites, comprising a serine 
residue (Murakami and Kudo, 2002). These isoforms are produced by 
alternative splicing of the 2880-nucleotide long mRNA (Kramer and 
Sharp, 1997). The cPLA2 mRNA and protein are expressed at very low 
basal levels in neurons and astrocytes (Owada et al., 1994, Ong et al., 
1999, Farooqui et al., 2000). High cPLA2 activity is found in the 
hindbrain of rats (Ong et al., 1999). It is also found in the white matter 
of murine fibrous astrocytes and gray matter of pial astrocytes (Lautens 
et al., 1998), as well as in brain astrocytes of humans (Stephenson et 
al., 1994).  
 
2.3.2 Function of cPLA2 in the brain 
 Cytosolic PLA2 catalyses the breakdown of membrane 
glycerophospholipids to generate arachidonic acid and lyso-platelet 
activating factor (PAF) (Winstead et al., 2000, Tanaka et al., 2012). It 
does not require calcium for catalysis but micromolar amounts are 
necessary for targeting to the membrane for function (Winstead et al., 
2000).Unlike cPLA2α, cPLA2ß and cPLA2γ has phospholipase A1 
activity and catalyses the hydrolysis of fatty acids at the sn-1 position 
as well, with a lower rate of function compared to cPLA2α (Murakami 
and Kudo, 2002). Arachidonic acid released is mainly responsible for 





Arachidonic acid undergoes further catalysis by lipoxygenases (LOXs) 
or cyclooxygenases (COXs) to generate proinflammatory eicosanoids 
such as leukotrienes, prostaglandins, thromboxanes, and PAF (Serhan 
et al., 1996).  
 cPLA2 is involved in neural plasticity, cell growth and 
regeneration, generation of second messenger and neurodegeneration 
(Farooqui et al., 2000). In terms of neural plasticity, Ca2+ influx 
activates cPLA2 and generates secondary messengers such as 
arachidonic acid, nitric oxide and PAF (Farooqui et al., 2000). These in 
turn serve as retrograde messengers that initiate and maintain LTP 
(Farooqui et al., 2000). cPLA2 is also associated with axonal growth, 
though the mechanism is not clear. Excessive release of 
proinflammatory mediators as a result of cPLA2 activity, together with 
ROS-stimulated oxidative stress, may drive the onset of 
neurodegeneration (Farooqui et al., 2000). These undesirable effects of 









Epigenetics is the study of heritable changes in gene function 
which are not a result of alterations in DNA sequence (Russo et al., 
1996). DNA is packed into highly compact states known as chromatin, 
which comprise basic repeating units known as nucleosomes 
(Kornberg, 1974). Each nucleosome is an octamer of two each of 
histones H2A, H2B, H3 and H4, wrapped around 147 base pairs of 
DNA (Allis et al., 2007). Epigenetic regulation involves covalent and 
non-covalent alterations to the DNA itself and the proteins associated 
with it (Allis et al., 2007). The epigenetic pathway typically involves 
three steps – (1) reception of environmental signal which triggers an 
intracellular process, (2) initiation of epigenetic modifications within the 
chromatin, and (3) maintenance of the modifications (Berger et al., 
2009). Environmental factors that induce epigenetic modifications 
include diet, physical exercise, lifestyle, pollutants and toxic insults 
(Berger et al., 2009).  
The four main types of epigenetic modifications are histone 
modification, DNA methylation, nucleosome remodeling and RNA-
mediated pathways (Allis et al., 2007, Portela and Esteller, 2010). DNA 
methylation correlates with gene silencing and involves addition of a 
methyl group at cytosine residues of DNA via the activity of DNA 
methyltransferases (Kalaria et al., 2008). Histone modifications and 
DNA methylation are relatively prominent and well-studied mechanisms 





3.1 Histone modifications and chromatin structure 
 Histones undergo different modifications such as methylation, 
acetylation and phosphorylation (Jenuwein and Allis, 2001). A compact 
chromatin state occurs when there are high levels of attraction between 
positively-charged histone tails and negatively-charged DNA (Herranz 
and Esteller, 2007). Histone modifications thus affect chromatin 
structure by altering the level of attraction between the DNA and the 
histone tails (Herranz and Esteller, 2007).  
 
Figure 3.1 Effect of HDACs, HATs, and respective inhibitors on 
regulation of chromatin conformation. HDAC, histone deacetylase; 
HAT, histone acetyltransferase. [Adapted from (Chuang et al., 2009)] 
 
 Figure 3.1 provides an illustration of the effects of HDACs and 
HATs on regulation of chromatin conformation, via regulation of 





and Allis, 1999). Acetylations of histone lysine (K) residues lead to 
neutralization of the positive histones, facilitating open chromatin 
structure and increased gene transcription (Herranz and Esteller, 
2007). Histone hyperacetylation generally gives rise to euchromatic 
chromatin conformation and thus more active transcription, while 
histone hypoacetylation facilitates a more transcriptionally inactive, 
heterochromatic state (Herranz and Esteller, 2007). Besides histone 
acetylation, histone methylations also occur and are catalysed by 
specific histone methyltransferases (HMTs) and histone demethylases. 
Selective and non-selective inhibitors of these enzymes have been 
developed in the study of epigenetics. Table 3.1 provides a summary of 
the functions of some well-known inhibitors of HDACs, HATs and 
HMTs, together with the histone residues affected and the 
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3.1.1 Histone acetyltransferases (HATs)  
 HATs catalyse the acetylation of histones by transferring an 
acetyl group from acetyl-CoA to lysine residues found on histone tails 
(Allis et al., 2007). HATs are typically characterized by presence of an 
acetyltransferase domain, and are broadly classified into five families, 
namely GCN5/PCAF, MYST (MOZ, YBF2/SAS3, SAS2, Tip60), TAFII 
250, CBP/p300 and SRC (Marmorstein, 2001). They are classified 
based on sequence homology, protein structure and substrate 
specificity (Kuo and Allis, 1998). HATs produce acetylated histones 
that recruit proteins containing bromodomains (Bottomley, 2004). 
Abnormal function of the CBP/p300 class of HAT has been associated 
with cancer by affecting cell cycle regulation and apoptotic genes (Iyer 
et al., 2004). The GCN5/PCAF HAT is known to interact with E2F, a 
transcription factor that promotes S-phase cell cycle progression 
(Taubert et al., 2004). Both PCAF and p300 have been found to 
catalyse acetylation of the tumor suppressor p53 protein, in turn 
affecting apoptosis (Liu et al., 1999). Taken together, it is observed that 
HATs play crucial roles in regulation of cell proliferation and apoptosis.  
 Specific inhibitors of HATs have been synthesized to study the 
roles of HATs in histone acetylation and gene transcription (Lau et al., 
2000). HATs also catalyse unique modifications on lysine substrates – 
for instance, p300 has a preference for the lysine 8 residue of histone 
H4 (H4K8), while PCAF enzymes selectively acetylates H3K14 (Schiltz 





HATs and HAT inhibitors. Thus, it is possible that HAT inhibitors can 
regulate gene expression. 
 
3.1.2 Histone deacetylases (HDACs) 
 HDACs catalyse the removal of acetyl groups from lysine 
residules of histone tails, thereby modifying chromatin structure (Allis et 
al., 2007). They are classified according to their homology to yeast 
HDACs, namely the class I, II and IV Zn2+-dependent enzymes and 
class III Zn2+-independent enzymes (de Ruijter et al., 2003, Chuang et 
al., 2009). HDAC11 is the only class IV enzyme, recently identified by 
its distinct structure (Voelter-Mahlknecht et al., 2005). Class I HDACs 
comprise HDAC1, 2, 3, and 8, due to their homology to yeast RPD3 
HDACs (Chuang et al., 2009, Delcuve et al., 2012b). Class II HDACs 
are related to yeast HDA1 HDACs and are sub-divided into class IIa 
and class IIb (Chuang et al., 2009, Delcuve et al., 2012b). Class IIa 
comprise HDAC4, 5, 7 and 9 while class IIb include HDAC6 and 10 
(Chuang et al., 2009, Delcuve et al., 2012b). Class III enzymes, also 
known as silent information regulator-like (sirtuins or SIRT) HDACs, 
comprise seven subtypes and the NAD+ cofactor is important for their 
activity (Chuang et al., 2009, Delcuve et al., 2012b). Class I HDACs are 
nuclear enzymes that play a role in cell proliferation and survival (Luo 
et al., 2009, Marks, 2010). Dimerization is necessary for HDAC activity 





homodimers or heterodimers based on cell type (He et al., 2005, 
Yamaguchi et al., 2010).  
 Trichostatin A (TSA) and suberoylanilide hydroxamic acid 
(SAHA) are examples of general, non-selective HDAC inhibitors that 
inhibit class I, II and IV zinc-dependent HDACs (Chuang et al., 2009). 
Sodium butyrate and valproic acid inhibit class I and class IIa HDACs 
(Gurvich et al., 2004, Vrba et al., 2011). MS-275 is a synthetic class I 
specific inhibitor (Franci et al., 2013); while bufexamac, an anti-
inflammatory drug, is a class IIb selective HDAC inhibitor (Delcuve et 
al., 2012a). Tubacin is a HDAC6 inhibitor which selectively inhibits 
tubulin acetylation (Haggarty et al., 2003). Table 3.1 shows a summary 
of the most common HDACs and their relevant inhibitors. It is thus 
possible that HDAC inhibitors of various specificities differentially 
regulate gene expression. 
 
3.1.3 Histone methyltransferases (HMTs)  
 Methylations can occur on lysine and arginine residues of 
histone tails in the regulation of chromatin structure. Multiple 
methylated states are possible as lysine residues can be subjected to 
mono-, di- and tri-methylation, while arginine residues can be mono- or 
di-methylated (Allis et al., 2007). Specific HMTs transfer methyl groups 
to specific sites on histone residues (Rice and Allis, 2001). Histone 
methyltransferases include two broad classes, namely, histone lysine 





(PRMTs). HKMTs share the SET domain that contains the catalytic site 
allowing binding to S-adenosyl-L-methionine cofactor (Allis et al., 
2007). SET proteins give rise to methylated histones that can attract 
binding of other proteins through the presence of chromodomains 
(Bottomley, 2004). Some HKMTs identified to date are MLL1, 2, 3, 4, 5, 
hSET1A and hSET1B (Wang and Zhu, 2008). PRMTs identified so far 
include PRMT1 and PRMT4, which are involved in gene activation, and 
PRMT5, with gene repression (Strahl and Allis, 2000).  
 Synthetic inhibitors of HKMTs have developed recently in the 
study of epigenetic regulation, one of which is 5’-deoxy-5’-
methylthioadenosine (MTA), which inhibits Set1 HKMTs that facilitate 
H3K4 methylation (El Mansouri et al., 2011). Table 3.1 provides a 
description of the properties and effects of MTA on histone 
modification. Thus, it is possible that HMT inhibitors, such as MTA, can 
regulate gene expression. 
 
3.1.4 Histone demethylases  
 Demethylation of histone residues is relatively unclear. Lysine 
specific demethylase 1 (LSD1) is the first demethylase that was 
recently discovered, which removes methyl groups selectively from 
H3K4me and H3K9me and is involved in transcriptional repression 
(Allis et al., 2007). Five other demethylases of homologous structures 
are later identified, which are distinct from the structure of LSD1 (Allis 





removes methyl groups from distinct sites on histone tails (Trewick et 
al., 2005, Tsukada et al., 2006).  For instance, JHDM1 demethylates 
H3K36me1 and H3K36me3, while JHDM2A demethylates H3K9me1 
and H3K9me2 (Yamane et al., 2006). 
 Synthetic inhibitors of LSD1 and JmjC histone demethylase 
inhibitors are designed but their selectivities and potencies are still 
under development (Lohse et al., 2011).  
 
3.1.5 The ‘histone code’ hypothesis 
 Distinct patterns of covalent modifications on histone tails form 
‘epigenetic signatures’ on the genome (Strahl and Allis, 2000). These 
fixed patterns of modifications forms a ‘histone code’ that determines 
the accessibility of the chromatin to binding of transcription factors 
(Strahl and Allis, 2000). Figure 3.1.5 show the distinct residues on 
which specific covalent modifications occur, and these modifications in 







Figure 3.1.5 Illustration of three types of histone modifications, 
namely phosphorylation (white), acetylation (red) and methylation 
(yellow) that occur on specific residues of histone tails. HATs 
catalyse acetylation while HDACs catalyse deacetylation of histone 
tails, resulting in active and inactive genes respectively. Presence of 
such distinct patterns of modifications led to the ‘histone code’ 
hypothesis. [Adapted from (Fischer et al., 2010)] 
 
 Correlative studies show specific histone modifications to 
associate with varying transcriptional activities (Allis et al., 2007). For 
instance, H3K9ac is typically associated with transcriptional activation, 
while H3K9me, with transcriptional repression (Allis et al., 2007). 
Similarly, trimethylation of H3K4 is associated with open chromatin 
conformation and increased gene expression (Allis et al., 2007). Table 
3.1.5 shows the types of histone lysine modifications associated with 











Table 3.1.5  Types of histone lysine modifications [Adapted from 








activation H3 (K9, K14, K18, K56) 
Phosphorylation 
 
activation H3 (S10) 
Methylation activation 
 
H3 (K4, K36, K79) 
   
 repression H3 (K9, K27) 
H4 (K20) 
 
3.2 Epigenetics and neuroinflammation  
The role of epigenetics in age-related neurodegeneration has 
been established in recent years (Glass et al., 2010b). In line with the 
age-related nature of neurodegenerative diseases such as AD and PD, 
it is widely accepted that epigenetic changes accumulate in individuals 
over the course of their lifespan, leading to disease (Glass et al., 
2010b). Much research show that accumulation of stresses early in life 
could leave persistent and accumulating epigenetic marks in the 
genome, modifying behavioral function in the long run (Wilson, 2008, 
Khansari et al., 2009). A phenomenon known as an “age-specific 
epigenetic drift” has been reported in late-onset AD, where 
modifications in epigenetic signatures lead to gene expression and 
behavioral changes over time (Wang et al., 2008). Some of these 
involve dysregulated histone acetylation as observed in AD mouse 
models (Francis et al., 2009), as well as changes in DNA methylation 





et al., 2008, Wang et al., 2011). Aberrations in histone acetylation and 
HDAC activities have also been reported in Parkinson’s disease 
(Kontopoulos et al., 2006). 
Growing evidence show the involvement of epigenetic 
mechanisms in inflammation. Changes in DNA methylation levels in AD 
patients were associated with the expression of proinflammatory 
lipoprotein-associated PLA2 (Lp-PLA2) (Wilensky et al., 2008, Wang et 
al., 2011). HDAC6 and HDAC9 increase activation of anti-inflammatory 
T-lymphocytes by inducing the binding of transcription factor forkhead 
box P3 (Beier et al., 2011). Other histone modifiers, SIRT1 and SIRT6, 
alter the promoter-binding efficacy of the transcription factor NF-kB to 
inflammatory genes (Yoshizaki et al., 2010, Galli et al., 2011). 
Epigenetic regulation also affect transcription of the TNF-α gene, which 
may explain inter-individual variations in inflammatory responses 
(Sullivan et al., 2007). Together, these findings suggest that 
inflammatory responses involved in chronic neurodegeneration could 
be significantly influenced by epigenetic mechanisms. 
 
3.3 Epigenetics and apoptosis 
Apoptosis is the main process of cell death in chronic 
neurodegeneration (Mattson, 2000). HDAC inhibitors affect cell cycle 
regulation and apoptosis (Choi, 2005). For instance, TSA induces 
apoptosis and promotes anti-cancer activity in non-small cell lung 





HDAC inhibitors such as the anti-epileptic drug, valproic acid, also 
confer neuroprotection (Monti et al., 2009). HAT inhibitors can have 
anti-cancer (Gajer et al., 2015) as well as neuroprotective properties 
(Durham, 2012). To date, there is little knowledge about epigenetic 
mechanisms behind neuronal apoptosis. 






4.0 Nutraceuticals and phytochemicals 
 “Nutraceutical” is a portmanteau of two words “nutrition” and 
“pharmaceutical”, referring to food or food products that has health-
promoting and medicinal properties (Kalra, 2003). Stephen DeFelice 
(MD), who is the founder and chairman of the Foundation for 
Innovation in Medicine, Granford, NJ, coined the term (Brower, 1998). 
He defined nutraceutical as “a food (or part of a food) that provides 
medical or health benefits, including the prevention and/or treatment of 
a disease (Brower, 1998).” It is distinct from “functional food” as 
functional food supplies the body with sufficient nutrients for its 
survival, but nutraceuticals further prevent or treat a disease (Kalra, 
2003). It is also distinct from dietary supplements as it is presented as 
a conventional food rather than as in a pill or tablet (Kalra, 2003). 
Nutraceuticals possess anti-cytotoxic effects as they generate 
neurotrophic factors essential for improved cell viability (Blaylock and 
Maroon, 2012).  
 Phytochemicals are chemical constituents found naturally in 
plants that possess health-promoting effects, and are used widely in 
nutraceuticals. Three major classes of plant chemicals include phenolic 
metabolites, terpenoids and alkaloids together with other nitrogen-
containing plant constituents (Dillard and German, 2000). Phenolic 
metabolites originate from higher plants and are unique due to their 
solubility in water and many possess antioxidant properties (Bravo, 





based plants, the most studied of which are tocopherols, tocotrienols 
and carotenoids (Dillard and German, 2000). Other subclasses of 
terpenoids are phytosterols, phenolic acids, flavonoids and 
isoflavonoids (Dillard and German, 2000). Anacardic acid is an 
example of a flavonoid extract derived from cashew nuts that has anti-
inflammatory properties (Sung et al., 2008). Alkaloids include 
glucosinolates, which are present in cruciferous vegetables, and 
indoles which regulate cell cycle progression and cellular apoptosis 
(Dillard and German, 2000). 
 
4.1 Neuroprotective properties of nutraceuticals 
 Nutraceuticals have been identified as natural antioxidants that 
protect against neuronal death and neurodegeneration (Kelsey et al., 
2010). Epigallocatechin 3-gallate (EGCG), the flavonoid polyphenol 
present in green tea, is protective against oxidative stress in rat 
cerebellar granular neurons (Schroeder et al., 2009) and H2O2-induced 
neuronal death in motor neurons (Koh et al., 2004). Quercetin, a 
flavonoid polyphenol in apples, increases cell viability in H2O2-induced 
cell death in PC12 cells (Heo and Lee, 2004). It also suppresses 
hippocampal neuronal cell death in rats under ischemic conditions (Pu 
et al., 2007). Curcumin, a yellow, non-flavonoid polyphenol found in 
turmeric and curry powder, decreases ROS and enhances cell survival 
in N2a mouse neuroblastoma cells (Dutta et al., 2009). Curcumin also 





of the middle cerebral artery (Yang et al., 2009). Together, these show 
promising effects of nutraceuticals and phytochemicals on 
neuroprotection, and suggests that there might be many more yet to be 
discovered. 
  
4.2 Epigenetic properties of nutraceuticals 
 While it is known that nutraceuticals possess neuroprotective 
and antioxidant properties, little understanding exists regarding the 
mechanism and ways by which it exerts its function. Several 
nutraceuticals have been reported to possess epigenetic properties 
such as the regulation of SIRTs and HATs (Kelsey et al., 2010, 
Ghizzoni et al., 2011). Anacardic acid, a flavonoid derived from cashew 
nuts, is a well-known general HAT inhibitor that inhibits the p300/CBP, 
GCN5/PCAF and MYST family of HATs (Sung et al., 2008). Its HAT 
inhibitory activity gives rise to its anti-inflammatory effects in the 
inhibition of lipopolysaccharide-induced interleukin-8 (IL-8) expression 
in human alveolar epithelial cells (Yasutake et al., 2013). Plumbagin, a 
compound derived from the medicinal plant Plumbago zeylanica, 
inhibits the p300 HAT and downregulates NF-kB-dependent gene 
expression (Sandur et al., 2006, Ravindra et al., 2009). It is known to 
possess anti-cancer properties (Gomathinayagam et al., 2008). EGCG 
functions as a HAT inhibitor and is able to modify chromatin structures 
and via decrease in acetylation of histone tails (Choi et al., 2009, 





stimulates downregulation of NF-kB-dependent expression of various 
pro-inflammatory genes (Balasubramanyam et al., 2004). Thus, there 
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Current literature shows that cPLA2 plays an important role in 
neuroinflammation and neurodegeneration. The age-related and 
progressive nature of neurodegeneration suggests potential for the 
environment and epigenetic influences to affect the onset and 
progression of chronic neuroinflammation. Little is known concerning 
the epigenetic regulation of cPLA2. Hence, the present study was 
carried out to test the hypothesis that significant regulation of cPLA2 
occurs at the epigenetic level in SH-SY5Y human neuroblastoma cells. 
In the first part of the study, an initial screening was performed to 
elucidate the effects of the general HDAC inhibitor, TSA, on mRNA 
expression of PLA2 isoforms. More specific HDAC inhibitors were used 
to explore the effects of various classes of HDACs on cPLA2α and 
iPLA2ß expression. Co-treatments of HAT and HMT inhibitors with 
HDAC inhibitors were administered to study their effects on cPLA2 
regulation. We further explored the effects of TSA on specific histone 
modifications at the cPLA2 promoter with chromatin 
immunoprecipitation. Subsequently, we investigated the effects of HAT 
and HMT inhibitors in cell injury induced by TSA. Co-treatment with the 
cPLA2-selective inhibitor AACOCF3 was performed to test the 
hypothesis that TSA induces cell injury via cPLA2-related mechanisms.  
Nutraceuticals and phytochemicals are found to be anti-
inflammatory and neuroprotective, and many have epigenetic effects 
on gene expression. We next investigated the effects of the natural 
compound, Clinacanthus nutans (C. nutans), on cPLA2 regulation in 
Section II 
Aims of Study 
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SH-SY5Y human neuroblastoma cells. The HAT activity assay was 
used to test the hypothesis that C. nutans functions via HAT inhibitory 
properties. The role of C. nutans in modulation of cell viability was also 
investigated. It is hoped that our findings would provide insights into the 
epigenetic regulation of cPLA2 and elucidate the potential for 




















EFFECTS OF INHIBITORS OF HISTONE 
DEACETYLASES, HISTONE ACETYLTRANSFERASES 
AND HISTONE METHYLTRANSFERASES ON 








Gene expression can be regulated at multiple levels, namely the 
regulation of chromatin conformation, transcriptional regulation, RNA 
processing, mRNA stability, translational regulation and post-translational 
modifications such as glycosylation, phosphorylation and protein degradation 
(Alberts et al., 2002).  
 Transcriptional regulation plays an important role in cPLA2 expression 
(Cowan et al., 2004). The cPLA2 gene is located on chromosome 1q25, 
adjacent to the COX-2 locus (Newman et al., 1997, Ghosh et al., 2006). The 
primary promoter region occurs between 31 to 73 positions upstream of the 
transcriptional start site (Cowan et al., 2004). Several binding sites at this 
region have been identified and proposed to be important for gene regulation 
(Cowan et al., 2004). Cytokines and growth factors that interact at these 
binding sites influence transcription of the gene (Cowan et al., 2004, Tsou et 
al., 2007). Glucocorticoid growth factors stimulate cPLA2α expression in 
human amnion fibroblasts (Guo et al., 2010), and IL-1ß induces its 
upregulation in human rheumatoid arthritis synovial fibroblasts (Chi et al., 
2011). Post-transcriptionally, the mRNA can be alternately spliced to produce 
cPLA2α, cPLA2ß, cPLA2γ, cPLA2δ, cPLA2ε and cPLA2ζ isoforms, whereby the 
cPLA2α isoform is most studied (Ghosh et al., 2006). 
 Post-translational modifications also play a role in regulation of cPLA2 
(Leslie, 1997). Phosphorylation of the cPLA2 protein facilitates translocation 
from the cytosol to intracellular membranes where it carries out its function 





primary mouse astrocyte cultures with cytokines and ATP promotes 
phosphorylation of cPLA2 via PKC and ERK, followed by arachidonic acid 
release (Xu et al., 2003). TNF-α induces cPLA2 phosphorylation and 
arachidonic acid release via activation of the MAP kinase cascade and NF-κB 
(Hernandez et al., 1999). Specific phosphorylation events at the serine-515 
and serine-505 residues are important for generation of arachidonic acid in 
vascular smooth muscle cells (Pavicevic et al., 2008). 
Thus far, however, relatively little is known about epigenetic regulation 
of cPLA2. Epigenetic modifications are typically characterized by reversible 
changes in gene expression following environmental stimuli (Glass et al., 
2010a, Bayarsaihan, 2011) or dietary changes (Morris, 2009). Enzymes such 
as histone acetyltransferases (HATs), histone deacetylases (HDACs), histone 
methyltransferases (HMTs) and histone demethylases mediate epigenetic 
histone modifications and control the state of lysine residues (K) on histone 
tails (Allis et al., 2007). Specifically, acetylation of the lysine 9 residue of 
histone H3 (H3K9ac) is typically associated with activated genes (Nightingale 
et al., 2007, Wu et al., 2012b), and likewise, trimethylation of the lysine 4 
residue of histone 3 (H3K4me3) is associated with open chromatin 
conformation and increased gene expression (Allis et al., 2007). HDAC 
inhibitors such as TSA significantly alters approximately 2% of genes (Van 
Lint et al., 1996), and recent studies highlighted it as a potential drug 
candidate, especially in the field of cancer therapy (Mariadason et al., 2000). 
The present study was therefore carried out to investigate possible epigenetic 





histone acetylation and methylation on cPLA2 expression were explored, and 
possible changes in cell viability as a result of these changes, elucidated.   
 
1.2 Materials and Methods 
1.2.1 Materials 
 Treatments administered to SH-SY5Y cells were dimethyl sulfoxide 
(DMSO), trichostatin A (TSA), valproic acid (VPA), MS-275, tubacin, 
anacardic acid, curcumin (CCM), NU9056, C646, butyrolactone-3 (MB-3), 5’-
deoxy-5’-methylthioadenosine (MTA) and arachidonyl trifluoromethyl ketone 
(AACOCF3). DMSO, TSA, VPA, tubacin, CCM, C646 and MTA were 
purchased from Sigma (St. Louis, MO). MS-275 and MB-3 were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Anacardic acid was 
purchased from Calbiochem (San Diego, CA). NU9056 and AACOCF3 were 
purchased from Tocris Bioscience (Bristol, UK). The stock solutions were 
dissolved in DMSO and further diluted in cell culture medium prior to use, 
except VPA whereby distilled H2O was used instead due to better solubility. 
 
1.2.2 Cell culture  
  SH-SY5Y human neuroblastoma cells were obtained from American 
Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin (Gibco-
Invitrogen, Carlsbad, CA). This cell line is a suitable in vitro model for the 





express mature isoforms of the tau protein (Agholme et al., 2010). They 
possess several characteristics similar to dopaminergic neurons, and thus are 
suitable as a PD models as well (Constantinescu et al., 2007). SH-SY5Y cells 
are generally locked in an early neuronal differentiation phase (Gilany et al., 
2008, Lopes et al., 2010). SH-SY5Y cells differentiated by retinoic acid 
displayed increased tau phosphorylation on top of neuron-like characteristics 
(Jämsä et al., 2004). Retinoic acid treatment was also found to reduce 
HDAC1 binding to neuronal genes, bringing about changes to the epigenome 
(Ekici et al., 2008). Therefore, SH-SY5Y cells were not further differentiated 
wih retinoic acid, so that responses to treatments affecting the histones can 
be evaluated. The cells used were of a constant N-type origin, as inter-
conversion to S-type was shown in previous literature not to occur due to their 
copy number variants and genetic variation (Cohen et al., 2003, Do et al., 
2011). This excludes the possibility of changes in gene expression to be due 
to spontaneous inter-conversions between the cell types. Cells were grown in 
100 mm2 cell culture dishes and incubated at 37°C, 100% humidity with 95% 
air and 5% CO2. 
 
1.2.3  Cell treatments 
1.2.3.1 Dose-dependent treatments with histone deacetylase (HDAC) 
inhibitors 
 To examine the effects of different HDAC inhibitors on cPLA2 and iPLA2 
expression, dose-dependent treatments were administered to four groups of 





three groups with increasing doses of the HDAC inhibitors. Each group 
consists of four biological replicates. TSA was administered in increasing 
doses up to the IC50 value of 0.5 µM (Muhlethaler-Mottet et al., 2008). VPA 
was administered up to 1000 µM as considerable epigenetic effects were 
observed in SH-SY5Y cells up to that dose (Jeong et al., 2003). Tubacin is 
known to inhibit HDAC6 at micromolar doses (Zilberman et al., 2009), while 
MS-275 is known to display epigenetic effects in SH-SY5Y cells at 1-10 µM 
(Formisano et al., 2015). Cells were incubated with respective HDAC 
inhibitors or vehicle for 24 hours before harvesting. 
 
1.2.3.2 Dose-dependent treatment with general histone 
acetyltransferase (HAT) inhibitor, anacardic acid 
 To study the effect of the general HAT inhibitor anacardic acid on 
cPLA2 and iPLA2 expression, dose-dependent treatments of 10 µM, 20 µM 
and 30 µM anacardic acid were administered to four groups of SH-SY5Y cells, 
according to known doses where it exerts significant epigenetic effects (Sun et 
al., 2006a, Morimoto et al., 2008). DMSO was used as vehicle control, and 
each group consists of four biological replicates. Anacardic acid is a well-
known HAT inhibitor that is a flavonoid extract derived from cashew nuts, and 
has been reported to possess anti-inflammatory properties (Sung et al., 2008). 








1.2.3.3 Dose-dependent treatment with natural p300-specific HAT 
inhibitor, curcumin (CCM) 
 To explore the effect of the natural p300-specific HAT inhibitor, CCM, 
on cPLA2 and iPLA2 expression, dose-dependent treatments of 10 µM, 20 µM 
and 30 µM curcumin were administered to four groups of SH-SY5Y cells, 
according to known doses where it exerts significant epigenetic effects 
(Huang et al., 2014). DMSO was used as vehicle control, and each group 
consists of four biological replicates. CCM is a component of Curcuma longa, 
commonly known as turmeric (Reuter et al., 2011), and is a selective inhibitor 
of p300 HAT (Marcu et al., 2006). Cells were incubated with CCM or vehicle 
treatment for 24 hours before harvesting. 
 
1.2.3.4 Treatment with general HAT inhibitor, anacardic acid, and 
general HDAC inhibitor, TSA 
 To investigate the effect of the general HAT inhibitor anacardic acid 
and the general HDAC inhibitor TSA on cPLA2 expression, SH-SY5Y cells 
were divided into four groups and treated as follows: (1) DMSO as vehicle 
control, (2) 0.5 µM TSA, (3) 20 µM AA, (4) 20 µM AA and 0.5 µM TSA. Each 
group consists of four biological replicates. Cells were co-incubated with 
anacardic acid and TSA or vehicle for 24 hours before harvesting. 
 
1.2.3.5 Treatment with natural p300-specific HAT inhibitor, CCM, and 
general HDAC inhibitor, TSA 





and the general HDAC inhibitor TSA on cPLA2 expression, four groups of SH-
SY5Y cells were treated as follows: (1) DMSO as vehicle control, (2) 0.5 µM 
TSA, (3) 20 µM CCM, (4) 20 µM CCM and 0.5 µM TSA. Each group consists 
of four biological replicates. Cells were co-incubated with CCM and TSA or 
vehicle for 24 hours before harvesting. 
 
1.2.3.6 Treatment with synthetic p300-specific HAT inhibitor, C646, 
and general HDAC inhibitor, TSA 
 To study the effect of the synthetic p300-specific HAT inhibitor C646 
and the general HDAC inhibitor TSA on cPLA2 expression, four groups of SH-
SY5Y cells were treated as follows: (1) DMSO as vehicle control, (2) 0.5 µM 
TSA, (3) 20 µM C646, (4) 20 µM C646 and 0.5 µM TSA. The doses were 
chosen according to doses of anacardic acid and curcumin used, so as to 
ensure consistency. Each group consists of four biological replicates. Cells 
were co-incubated with C646 and TSA or vehicle for 24 hours before 
harvesting. 
 
1.2.3.7 Treatment with GCN5-specific HAT inhibitor, MB-3, and 
general HDAC inhibitor, TSA 
 To explore the effect of the GCN5-specific HAT inhibitor MB-3 and the 
general HDAC inhibitor TSA on cPLA2 expression, SH-SY5Y cells were 
divided into four groups and treated as follows: (1) DMSO as vehicle control, 
(2) 0.5 µM TSA, (3) 20 µM MB-3, (4) 20 µM MB-3 and 0.5 µM TSA. The doses 





to ensure consistency. Each group consists of four biological replicates. Cells 
were co-incubated with MB-3 and TSA or vehicle for 24 hours before 
harvesting. 
 
1.2.3.8 Treatment with Tip60-specific HAT inhibitor, NU9056, and 
general HDAC Inhibitor, TSA 
 To investigate the effect of the Tip60-specific HAT inhibitor NU9056 
and the general HDAC inhibitor TSA on cPLA2 expression, SH-SY5Y cells 
were divided into four groups and treated as follows: (1) DMSO as vehicle 
control, (2) 0.5 µM TSA, (3) 20 µM NU9056, (4) 20 µM NU9056 and 0.5 µM 
TSA. The doses were chosen according to doses of anacardic acid and 
curcumin used, so as to ensure consistency. Each group consists of four 
biological replicates. Cells were co-incubated with NU9056 and TSA or 
vehicle for 24 hours before harvesting. 
 
1.2.3.9 Treatment with Tip60-specific HAT inhibitor, NU9056, and 
class I-specific HDAC inhibitor, MS-275 
 To examine the effect of the Tip60-specific HAT inhibitor NU9056 and 
the class I-specific HDAC inhibitor MS-275 on cPLA2 expression, SH-SY5Y 
cells were divided into four groups and treated as follows: (1) DMSO as 
vehicle control, (2) 5 µM MS-275, (3) 20 µM NU9056, (4) 20 µM NU9056 and 
5 µM MS-275. Each group consists of four biological replicates. Cells were co-






1.2.3.10 Treatment with histone methyltransferase (HMT) inhibitor, 
MTA, and general HDAC inhibitor, TSA 
 To study the effect of the HMT inhibitor MTA and the general HDAC 
inhibitor TSA on cPLA2 expression, four groups of SH-SY5Y cells were treated 
as follows: (1) DMSO as vehicle control, (2) 0.5 µM TSA, (3) 200 µM MTA, (4) 
200 µM MTA and 0.5 µM TSA. MTA reduces trimethylation of H3K4 at 
micromolar doses via the inhibition of Set1 methyltransferases (Huang et al., 
2006, El Mansouri et al., 2011). Each group consists of four biological 
replicates. Cells were co-incubated with MTA and TSA or vehicle for 24 hours 
before harvesting. 
 
1.2.4 Real-time quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) 
 Total RNA extraction from SH-SY5Y cells was performed with the 
RNeasy Mini kit (Qiagen, Hamburg, Germany). Reverse transcription of RNA 
to complementary DNA (cDNA) was performed using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA), with the 
thermal cycler of reaction conditions set at 25°C for 10 minutes, 37°C for 120 
minutes, and 85°C for 5 seconds. The cDNA obtained was quantified by real-
time RT-PCR using the TaqMan® Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA) with TaqMan® Gene Expression Assay Probes 
for cPLA2α (Hs00233352_m1), iPLA2β (Hs00185926_m1), and β-actin 
(#4326315E) (Applied Biosystems, Foster City, CA). Real-time RT-PCR was 





Biosystems, Foster City, CA), and run on the Applied Biosystem 7500 Real-
Time PCR system. Reaction conditions were set at an initial incubation of 
50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute.  
 Relative amounts of gene transcript were estimated after normalization 
to β-actin, the endogenous control gene. It is a suitable endogenous control 
as it was shown to be unaffected by TSA treatment in a previous study (Makki 
et al., 2008).  Using the 2-ΔΔCT method as previously described (Livak and 
Schmittgen, 2001), the relative fold changes were quantified. The mean and 
standard error were then calculated and significant differences analysed using 
one-way analysis of variance (ANOVA) with Bonferroni’s multiple comparison 
post-hoc test, where P < 0.05 was deemed significant. 
 
1.2.5 Western blots 
 Protein samples were extracted by lysing cell samples in 
radioimmunoprecipitation assay (RIPA) buffer (Cell Signaling Techonology, 
Boston, MA), supplemented with HaltTM protein and phosphatase inhibitor 
cocktail and EDTA solution (#78440, Pierce, Rockford, IL). Lysed samples 
were incubated at 4ºC for one hour and subsequently centrifuged at 14,000 g, 
and 4ºC, for one hour to separate cellular protein extracts from cell debris. 
Protein quantification was performed using the Bio-Rad protein assay dye 
(Bio-Rad Laboratories, Hercules, CA). 30 µg of protein were loaded and 
separated by molecular mass in 10% SDS-polyacrylamide gel via 





difluoride (PVDF) membrane (Thermo Fisher Scientific, Waltham, MA) for 1 
hour 10 minutes, 20V. Non-specific binding sites on the membrane was 
blocked with 3-5% bovine-serum albumin (BSA) in tris-buffered saline with 
0.1% Tween-20 (TBST) for one hour, followed by overnight incubation with 
rabbit polyclonal anti-cPLA2 (sc-438, 1:500 in 3% BSA, Santa Cruz 
Biotechnology, Santa Cruz, CA; #2832S, 1:500 in 5% BSA, Cell Signaling 
Technology, Beverly, MA), at 4ºC. Following overnight incubation, the 
membrane was subject to six washes, followed by secondary antibody 
incubation with horseradish peroxidase conjugated with anti-rabbit IgG 
(1:2000 in blocking buffer, Pierce, Rockford, IL) for 1 hour at r.t.p. 
Immunolabeled proteins were then visualized with the enhanced 
chemiluminescence reagent, LuminataTM Crescendo Western HRP Substrate 
(Millipore, Billerica, MA), according to the manufacturer’s protocol. ß-actin was 
labelled to verify equal loading using a mouse monoclonal antibody (1:10,000 
in 3-5% BSA, Sigma, St. Louis, MO) and its corresponding secondary 
antibody. Densitometric analyses of the bands were performed using the 
GelPro software (Media Cybernetics, Maryland, VA). The relative densities of 
target bands were normalised against those of ß-actin, and the mean and 
standard errors calculated. Significant differences between groups were 
analysed using the one-way ANOVA with Bonferroni’s multiple comparison 









 SH-SY5Y cells were counted and 2 x 105 cells were cultured on poly-L-
lysine-coated coverslips placed in 24-well plates. They were grown to 80% 
confluency before administration of treatment. The cells were incubated with 
treatment for 24 hours. The next day, cells were fixed with 4% 
paraformaldehyde, followed by antigen retrieval with formic acid for 30 
minutes; and subsequently, permeabilization with 0.1% Triton-X for five 
minutes. They were then blocked in 3% BSA, and incubated overnight with 
cPLA2 specific antibody (sc-438, 1:50 in 3% BSA, Santa Cruz Biotechnology, 
Santa Cruz, CA), followed by secondary antibody incubation with the anti-
rabbit Alexa Fluor 488 (Applied Biosystems, Foster City, CA; diluted 1:200). 
Nuclei were labelled and coverslips mounted with the Prolong Gold Anti-fade 
Mountant DAPI (Invitrogen, Carlsbad, CA). After thorough drying, the samples 
were analysed and images captured using confocal microscopy (Zeiss, Jena, 
Germany).  
 
1.2.7 Quantitative image analysis  
To measure the fluorescence intensity of cells between the treatment 
groups, images were captured using the confocal microscope (Zeiss, Jena, 
Germany) at the plane with the best focus. An average of ten to fifteen images 
were captured per treatment group. The region around each cell was 
demarcated and measured with the Image J software (Burgess et al., 2010, 
Gavet and Pines, 2012). Background readings were obtained by obtaining 





intensity was calculated for each image according to the following formula: 
Corrected total cell fluoresence (CTCF) = Integrated Density – (Area of 
selected cell x Mean fluorescence of background readings). Net average 
intensity values were then normalised against vehicle-treated controls. The 
mean and standard errors were calculated and significant differences 
analysed using one-way ANOVA with Bonferroni’s multiple comparison post-
hoc test, where P < 0.05 was deemed significant.  
 
1.2.8 Chromatin immunoprecipitation real-time polymerase chain 
reaction (ChIP-qPCR) 
1.2.8.1 Determination of specific histone binding sites on cPLA2 gene 
In order to determine histone-rich regions on the cPLA2α gene for 
downstream primer design, we used a database of ChIP-sequencing 
experiments known as the Human Epigenome Atlas, release 9 (Zhou et al., 
2011, Medicine, 2013). The Browser hosts sequencing experiment tracks from 
the Encyclopedia of DNA Elements (ENCODE) and Roadmap Epigenomics 
Project (Consortium, 2011, Epigenomics, 2015). The ENCODE Consortium is 
made up of research groups under international collaboration funded by the 
National Human Genome Research Institute (NHGRI) (Consortium, 2011). A 
detailed description of the precise standards and considerations for evaluating 
the quality of ChIP-seq data and antibodies used for ChIP-seq is available 
(Consortium, 2011). The Roadmap Epigenomics Project is an international 
collaboration and a detailed research workflow and list of participants and 





sites on the cPLA2α gene, we used the University California Santa Cruz 
(UCSC) Genome Browser (Kent et al., 2002) to determine the loci of the 
cPLA2α gene on the human genome. Together, both databases allowed us to 
determine the binding sites of specific histones of interest at the cPLA2α 
promoter, for verification by chromatin Immunoprecipitation real-time 
polymerase chain reaction (ChIP-qPCR). 
 
1.2.8.2 Primer design 
 In order to design primers for ChIP-qPCR, we chose to obtain ChIP-
sequencing data of H3K4me3 and H3K9ac from the Human Epigenome Atlas 
because of their known associations with activated genes (Nightingale et al., 
2007, Wu et al., 2012b). The human cell types analysed were the H1-derived 
neuronal progenitor cultured cells and H9-derived neuron cultured cells, 
chosen because of their relatively close association with SH-SY5Y human 
neuroblastoma cells. For each of the six samples analysed, histone-enriched 
regions were determined by observing the peaks present. Primers used in the 
ChIP experiment were designed based on these regions identified. A set of 
forward (5”-CCTCCTTAGCTTTTACTTGG-3”) and reverse primers (5”-
GGATTCCAACCCAAAGAAAC-3”) (bp +143 to +349) was used for detection 
of the cPLA2α gene region of interest, encoding a 206 base-pair long region. 
The amplification efficiencies of the primers were optimized by performing 
serial dilutions of the primers followed by multiple trials of qPCR using 
different temperature settings. The optimal annealing temperature was 





qPCR of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter 
was performed with the forward primer (5”-TACTAGCGGTTTTACGGGCG-3”) 
and the reverse primer (5”-TCGAACAGGAGGAGCAGAGAGCGA-3”) 
(provided in kit).  
 
1.2.8.3 ChIP-qPCR 
 ChIP-qPCR was carried out to investigate the involvement of a specific 
region on the cPLA2α gene in TSA-induced cPLA2α expression. SH-SY5Y 
cells were cultured on 150 mm dishes and grown to 80% confluency. Cells 
were treated with DMSO as vehicle control or with 0.5 µM TSA, and 
subsequently incubated for 24 hours prior to performing the ChIP assay, 
according to the protocol as provided by the EZ-Magna ChIPTM A Chromatin 
Immunoprecipitation Kit (#17-408, Millipore, Billerica, MA). Cells were 
harvested on ice-cold phosphate-buffered saline (PBS) and crosslinked in 1% 
formaldehyde. Chromatin samples were sonicated with a Vibra-cellTM 
sonicator (Sonics and Materials Inc., Danbury, CT) to obtain DNA fragments 
ranging from 200 to 800 base pairs. The sonication conditions were 14 cycles 
of 10-second pulses and 30-second pauses, at 40% amplitude. The samples 
were then run on 1.5% agarose gel to confirm shearing efficiency. The 
sheared stock was then aliquoted in 50 µl amounts separated into 1.5 ml 
tubes for storage at -80°C. Three tubes from each treatment group were used 
for the antibody incubation, before which, 1% of total chromatin in each 
reaction tube was saved as ‘input’ for later analysis.  





overnight with rotation at 4°C. The antibodies used were histone Protein A 
purified IgG raised in rabbit (provided in kit), ChIPAb+ Trimethyl-Histone H3 
(Lys4) (#17-614, Millipore, Billerica, MA) and ChIPAb+ Acetyl-Histone H3 
(Lys9) (#17-658, Millipore, Billerica, MA). After overnight incubation, the 
samples were subjected to reverse crosslinking and purification. The enriched 
DNA and ‘input’ samples were quantified by SYBR green real time RT-PCR, 
using optimised primers specific for the region +143 to +349 base pairs 
downstream from the transcriptional start site of the cPLA2α gene. 
Subsequently, the percent enrichment of immunoprecipitated DNA relative to 
input chromatin was calculated. All quantitative ChIP assay results are 
presented as the averages from three independent immunoprecipitations. The 
mean and standard error were then calculated, and significant differences 
were analysed using the Student’s t-test, where P < 0.05 was deemed as 
significant. 
 
1.2.9  Detection of H3K9 acetylation levels 
 Detection of H3K9 acetylation was performed using the EpiQuikTM In 
Situ Histone H3K9 Acetylation Assay Kit (#P-4004, Epigentek, Farmingdale, 
NY). Cells were cultured in a 96-well microplate (provided in kit) and grown to 
80% confluency. They were classified into two treatment groups (1) DMSO 
vehicle control, (2) 0.5 µM TSA, and untreated controls. Each group consists 
of four biological replicates. After treatment, cells were incubated overnight for 
24 hours before the assay was performed according to the manufacturer’s 





reader (Tecan Group Ltd., Maennedorf, Switzerland) at a wavelength of 450 
nm within 10 minutes, and the % H3K9 acetylation was calculated according 
to the following formula: 
Acetylation %  =   O. D. (treated sample-blank)O.D. (untreated control-blank)  x 100 
Average values were then normalised against untreated controls and plotted 
on a graph. The mean and standard error were calculated, and significant 
differences analysed using the Student’s t-test, where P < 0.05 was deemed 
significant. 
 
1.2.10 Lactate dehydrogenase (LDH) assay 
 SH-SY5Y cells were counted and 2 x 105 cells were cultured in 24-well 
plates, and grown to 80% confluency before administration of treatment. 
AACOCF3 was used for the selective inhibition of cPLA2 enzyme activity, 
since it is known to be 500-fold more potent in blocking cPLA2 activity at 15 
µM as compared to iPLA2 and sPLA2 (Trimble et al., 1993, Liu et al., 2014). 
Cell viability was accessed after 24 hours by colorimetric determination of 
lactate dehydrogenase (LDH) release, using the LDH Cytotoxicity Detection 
Kit (Roche, Mannheim, Germany), according to manufacturer’s protocol. 
Percentage of cell death was calculated and the average of three plate 
readings taken. The plate was read at an excitation wavelength of 490 nm on 
the Tecan Infinite® 200 microplate reader (Tecan Group Ltd., Maennedorf, 
Switzerland). The reference absorbance reading was subtracted from the 






Cytotoxicity   %   =   experimental value-low controlhigh control-low control  × 100  
The mean cytotoxicity values were then normalised against vehicle-treated 
controls. The mean and standard errors were calculated, and significant 
differences analysed using one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test, where P < 0.05 was deemed significant. 
 
1.3   Results 
1.3.1 Effect of HDAC inhibitors on cPLA2α and iPLA2ß mRNA 
expression 
1.3.1.1 Trichostatin A (TSA) 


























   
Figure 1.3.1.1 Real-time RT-PCR analyses of (A) cPLA2α and (B) iPLA2ß 
mRNA expression after dose-dependent treatment with general HDAC 
inhibitor, trichostatin A (TSA). Data represent mean and standard error of 
four biological replicates. Statistical analysis by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. * Indicates significant 
difference compared to DMSO-treated vehicle controls. * P < 0.05 and *** P < 
0.001. 
  
 Significant increases in cPLA2α mRNA expression by 59.2-fold and 
413.3-fold were observed after treatment with 0.25 µM and 0.5 µM TSA 
respectively, compared to DMSO-treated vehicle controls (P < 0.001) (Fig. 
1.3.1.1 A). A relatively small but significant 6.4-fold increase in iPLA2ß mRNA 































Figure 1.3.1.2 Real-time RT-PCR analyses of (A) cPLA2α and (B) iPLA2ß 
mRNA expression after dose-dependent treatment with class IIa HDAC 
inhibitor, valproic acid (VPA). Data represent mean and standard error of 
four biological replicates. Statistical analysis by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. * Indicates significant 
difference compared to dH2O-treated vehicle controls. * P < 0.05, ** P < 0.01 
and *** P < 0.001.  
 
Significant increases in cPLA2α mRNA expression by 15.1-fold and 











































respectively, compared to dH2O-treated vehicle controls (P < 0.001) (Fig. 
1.3.1.2 A). In contrast, a small but significant 2.0-fold decrease in iPLA2ß 
expression was observed after treatment with 1000 µM VPA, compared to 










































Figure 1.3.1.3 Real-time RT-PCR analyses of (A) cPLA2α, (B) iPLA2ß 
mRNA expression after dose-dependent treatment with HDAC6-specific 
inhibitor, tubacin. Data represent mean and standard error of four biological 
replicates. Statistical analysis by one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. * Indicates significant difference compared to 
DMSO-treated vehicle controls. * P < 0.05, ** P < 0.01. 
 
A small but significant 2.2-fold increase in cPLA2α mRNA expression 
was observed after treatment with 15 µM tubacin, compared to DMSO-treated 
vehicle controls (P = 0.016) (Fig. 1.3.1.3 A). Similarly, a significant 2.3-fold 
increase in iPLA2ß mRNA expression was observed after treatment with 15 
































   
Figure 1.3.1.4 Real-time RT-PCR analyses of (A) cPLA2α, (B) iPLA2ß 
mRNA expression after dose-dependent treatment with class I HDAC 
inhibitor, MS-275. Data represent mean and standard error of four biological 
replicates. Statistical analysis by one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. * Indicates significant difference compared to 
DMSO-treated vehicle controls. * P < 0.05 and *** P < 0.001. 
 
Significant increases in cPLA2α mRNA expression by 18.3-fold, 3750-
fold and 4600-fold were detected after treatments with increasing doses of 1 
µM, 5 µM and 10 µM MS-275 respectively, compared to DMSO-treated 
vehicle controls (P < 0.001) (Fig. 1.3.1.4 A). In contrast, no significant 






















1.3.2  Effect of HAT inhibitors on cPLA2α and iPLA2ß mRNA expression 
1.3.2.1 Anacardic acid (AA)  
  
  
Figure 1.3.2.1 Real-time RT-PCR analyses of (A) cPLA2α and (B) iPLA2ß 
mRNA expression after dose-dependent treatment with general HAT 
inhibitor, anacardic acid (AA). Data represent mean and standard error of 
four biological replicates. Statistical analysis by one-way ANOVA with 




































No significant changes in cPLA2α and iPLA2ß mRNA expression were 
observed after dose-dependent treatment with anacardic acid, compared to 
DMSO-treated vehicle controls (Fig. 1.3.2.1). 
 
1.3.2.2 Curcumin (CCM) 
   






































Figure 1.3.2.2 Real-time RT-PCR analyses of (A) cPLA2α, (B) iPLA2ß 
mRNA expression after dose-dependent treatment with natural p300-
specific HAT inhibitor, curcumin (CCM). Data represent mean and 
standard error of four biological replicates. Statistical analysis by one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc test.  
 
No significant changes in cPLA2α and iPLA2ß mRNA expression were 
observed after dose-dependent treatment with curcumin, compared to DMSO-
treated vehicle controls (Fig. 1.3.2.2). 
 
1.3.3 Effect of HAT and HDAC inhibitor co-treatments on cPLA2 
expression 
1.3.3.1 General HAT inhibitor, anacardic acid, and general HDAC 
inhibitor, TSA 










































































Figure 1.3.3.1 Effect of general HAT inhibitor, anacardic acid (AA), and 
general HDAC inhibitor, TSA treatment.  (A) Real-time RT-PCR analyses 
of cPLA2α mRNA expression. (B) Immunocytochemistry photos of cPLA2 
protein expression in SH-SY5Y cells after AA and TSA treatment. (C) 
Quantification of ten high-power microscopic fields from four biological 
replicates per group analysed and computed as average corrected total cell 
fluorescence (CTCF) values. Scale bar = 20 µm. AFU: arbitrary fluorescence 
units. Data represent mean and standard error of four biological replicates. 
Analysed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc 
test. * Indicates significant difference compared to DMSO-treated vehicle 
controls, *** P < 0.001. # indicates significant difference compared to cells 
treated with 0.5 μM TSA, ### P < 0.001. 
 
A significant 157.6-fold increase in cPLA2α mRNA expression was 
observed after treatment with 0.5 µM TSA, compared to DMSO-treated 
vehicle controls (P < 0.001). Interestingly, co-treatment of 20 µM anacardic 
acid with 0.5 µM TSA significantly suppressed the effect of TSA treatment on 
cPLA2α mRNA expression by 53.3%, compared to cells treated with TSA only 
(P = 0.0201) (Fig. 1.3.3.1 A).  
Presence of cPLA2 immunoreactivity was detected in both the nucleus 
and cytoplasm of SH-SY5Y cells (Fig. 1.3.3.1 B). Significant increase in 
fluorescence intensity was detected after treatment with 0.5 µM TSA, with an 
average fluorescence value of (1.4 x 105 arbitrary fluorescence units (AFU)), 
as compared to cells in the DMSO-treated vehicle control group with average 
fluorescence value of (4.1 x 104 AFU) (P < 0.001). Fluorescence intensity 
remained low (3.4 x 104 AFU) after treatment with anacardic acid alone. Co-
treatment of 20 µM anacardic acid with 0.5 µM TSA resulted in a significant 2-
fold reduction in average fluorescence value (6.6 x 104 AFU), compared to 






1.3.3.2 Specific HAT inhibitors and general HDAC inhibitor, TSA 
  
  
Figure 1.3.3.2 Real-time RT-PCR analyses of cPLA2α mRNA expression 
after treatment with specific HAT inhibitors. (A) Natural p300-specific 
inhibitor CCM and TSA, (B) Synthetic p300-specific inhibitor C646 and TSA, 
(C) GCN5 inhibitor MB-3 and TSA, (D) Tip60 inhibitor NU9056 and TSA. Data 
represent mean and standard error of four biological replicates. Analysed by 
one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. * 
Indicates significant difference compared to DMSO-treated vehicle controls, 
*** P < 0.001. # Indicates significant difference compared to cells treated with 
0.5 μM TSA, # P < 0.05. 
 
Significant increases in cPLA2α mRNA expression were observed in 
cells treated with 0.5 µM TSA, compared to DMSO-treated vehicle controls (P 
< 0.001). However, co-treatment of 20 μM curcumin, 20 µM C646, and 20 µM 
MB-3 with 0.5 µM TSA did not suppress cPLA2α mRNA expression (Fig. 
1.3.3.2 A-C).  
For the experiment using Tip60-specific HAT inhibitor, NU9056, a 
significant 2820-fold increase in cPLA2α expression was observed after 
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0.001) (Fig. 1.3.3.2 D). Interestingly, co-treatment of 20 µM NU9056 with 0.5 
µM TSA significantly suppressed the effect of TSA treatment on cPLA2α 
mRNA expression by 51.1%, compared to cells treated with TSA only (P = 
0.043) (Fig. 1.3.3.2 D). 
 
1.3.3.3  Tip60-specific HAT inhibitor NU9056 and class I-specific 
HDAC inhibitor, MS-275 
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Effect of MS-275 and NU9056 on cPLA2 Protein Expression
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Figure 1.3.3.3 Effect of Tip60-specific HAT inhibitor NU9056 and class I-
specific HDAC inhibitor, MS-275 treatment. (A) Real-time RT-PCR 
analyses of cPLA2α mRNA expression. (B) Western blot of cPLA2 protein 
expression after NU9056 and MS-275 treatment. (C) Densitometric analysis of 
the effect of NU9056 and MS-275 treatment on cPLA2 protein expression. (D) 
Immunocytochemistry photos of cPLA2 protein expression after NU9056 and 
MS-275 treatment. (E) Quantification of ten high-power microscopic fields 
from four biological replicates per group, analysed and computed as average 
corrected total cell fluorescence (CTCF) values. Scale bar = 20 µm. AFU: 
arbitrary fluorescence units. All data represent the mean and standard error of 
four biological replicates, analysed by one-way ANOVA with Bonferroni’s 
multiple comparison post-hoc test. * Indicates significant difference compared 
to the DMSO-treated vehicle controls, ** P < 0.01, *** P < 0.001. # indicates 
significant difference compared to cells treated with 5 μM MS-275, ## P < 0.01, 
### P < 0.001. 
 
 
A significant 10,700-fold increase in cPLA2α mRNA expression was 
observed after treatment with 5 µM MS-275, compared to DMSO-treated 
vehicle controls (P < 0.001). Co-treatment of 20 µM NU9056 with 5 µM MS-
275 significantly suppressed the effect of MS-275 treatment on cPLA2α mRNA 
expression by 59.2%, compared to cells treated with MS-275 only (P < 0.001) 
(Fig. 1.3.3.3 A).  
Western blot analysis detected a single band of ~85 kDa (Fig. 1.3.3.3 
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treated group, compared to DMSO-treated controls (P = 0.01) (Fig. 1.3.3.3 C). 
20 µM NU9056 treatment alone did not show significant changes from the 
control group, while co-treatment of 20 µM NU9056 with 5 µM MS-275 
showed significantly lower relative densities, compared to cells treated with 
MS-275 alone (P = 0.01) (Fig. 1.3.3.3 C).  
Presence of cPLA2 immunoreactivity was detected in both the nucleus 
and cytoplasm of SH-SY5Y cells (Fig. 1.3.3.3 D). Significant increase in 
fluorescence intensity was detected after treatment with 5 µM MS-275, with an 
average fluorescence value of (2.3 x 104 AFU), as compared to cells in the 
DMSO-treated vehicle control groups with average fluorescence value of (1.3 
x 104 AFU) (P < 0.001). Fluorescence intensity remained low (1.1 x 104 AFU) 
after treatment with NU9056 alone. Co-treatment of 20 µM NU9056 with 5 µM 
MS-275 resulted in a larger than 2-fold reduction in average fluorescence 
value (9.6 x 103 AFU), compared to cells treated with MS-275 alone (P < 







1.3.4  Effect of general HMT inhibitor, MTA and general HDAC inhibitor, 
TSA co-treatments on cPLA2 expression  
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Figure 1.3.4 Effect of HMT inhibitor MTA and general HDAC inhibitor, 
TSA on cPLA2 expression. (A) Real-time RT-PCR analyses of cPLA2α 
mRNA expression. (B) Western blot of cPLA2 protein expression after MTA 
and TSA treatment. (C) Densitometric analysis of the effect of MTA and TSA 
treatment on cPLA2 protein expression. (D) Immunocytochemistry photos of 
cPLA2 protein expression in SH-SY5Y cells after MTA and TSA treatment. (E) 
Quantification of ten high-power microscopic fields from four biological 
replicates per group, analysed and computed as average corrected total cell 
fluorescence (CTCF) values. Scale bar = 20 µm. AFU: arbitrary fluorescence 
units. All data represent the mean and standard error of four biological 
replicates, analysed by one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. * Indicates significant difference compared to the 
DMSO-treated vehicle controls, ** P < 0.01, *** P < 0.001. # indicates 
significant difference compared to cells treated with 0.5 μM TSA # P < 0.05, ## 
P < 0.01, ### P < 0.001. 
 
A significant 1885-fold increase in cPLA2α mRNA expression was 
observed in TSA-only treated groups, compared to DMSO-treated vehicle 
controls (P < 0.001). Co-treatment of 200 µM MTA with 0.5 µM TSA 
significantly suppressed the effect of TSA treatment by 59.5%, compared to 
cells treated with TSA only (P = 0.004) (Fig. 1.3.4 A).  
A single band of ~85 kDa was detected via Western blot (Fig. 1.3.4 B). 
Significant increases in relative densities were detected in the TSA-treated 
group, compared to DMSO-treated vehicle controls (P < 0.001) (Fig. 1.3.4 C). 
NU9056 treatment alone did not show significant changes from the control 
group, while co-treatment of 200 µM MTA with 0.5 µM TSA showed 
significantly lower relative densities, compared to cells treated with TSA alone 
(P < 0.01) (Fig. 1.3.4 B-C).  
Presence of cPLA2 immunoreactivity was detected in both the nucleus 
and cytoplasm of SH-SY5Y cells (Fig. 1.3.4 D). Significant increase in 
fluorescence intensity was detected after treatment with 0.5 µM TSA, with an 





DMSO-treated vehicle control groups with average fluorescence value of (4.3 
x 105 AFU) (P < 0.001). Fluorescence intensity remained low (1.3 x 106 AFU) 
after treatment with MTA alone. Co-treatment of 200 µM MTA with 0.5 µM 
TSA resulted in a significant reduction in average fluorescence value of (1.6 x 









Fig. 1.3.5.1 Shearing efficiency of DMSO control and TSA-treated 
chromatin analysed on 1.5% agarose gel. Lanes (left to right; 1-6): 100 bp 
ladder; unsheared DMSO control sample; sheared DMSO control sample; 
unsheared TSA control sample; sheared TSA control sample; 100 bp ladder. 























































Sheared DNA obtained from SH-SY5Y cells showed smear ranging 
from 200-800 base pairs (lanes 3 and 5), compared to unsheared controls 
(lanes 2 and 4) (Fig. 1.3.5.1).  
 







Fig. 1.3.5.2 University of California Santa Cruz (UCSC) genome browser 
screenshots and loci of primer design. (A) H3K9ac and (B) H3K4me3 
profiles in cPLA2α genome of H9 derived neuron cultured cells and H1 derived 
neuronal progenitor cultured cells. Box indicates histone-enriched region 
where primer design targeted. (C) Illustration showing loci where ChIP primers 
were designed based on alignment output: +143 to +349 downstream of the 
transcriptional start site of the cPLA2α gene. TSS: transcriptional start site of 

















 Sequence alignment of histone-enriched regions in two cell types of 
neuronal origin showed H3K9ac-rich (Fig. 1.3.5.2 A) and H3K4me3-rich (Fig. 
1.3.5.2 B) islands at the proximal promoter regions (1 kb upstream and 
downstream of transcriptional start site). The localisation of H3K9ac histones 
showed less specificity, while the localisation of H3K4me3 was found to be 
more distinct (boxed region, +143 to +349 from transcriptional start site). 
Primers were designed at +143 to +349 base pairs downstream from 

































Fig 1.3.5.3 Chromatin immunoprecipitation (ChIP) assay results. Fold 
enrichment of human cPLA2α gene region (+143 to +349) after 
immunoprecipitation with (A) anti-H3K9 acetylated (H3K9ac) and (B) 
anti-H3K4 trimethylated (H3K4me3) antibodies. Chromatin was 
immunoprecipitated using an anti-trimethyl-H3K4 and or anti-acetyl-H3K9 
antibody followed by quantitative real-time PCR of the purified DNA. 
Immunoprecipitation with an antibody against IgG was used as a negative 
control. One percent of the precipitated chromatin was assayed to verify equal 
loading (Input). Data were normalised to IgG threshold (CT) values and 
reported as fold enrichment of control (IgG) binding to site. Data represent the 
mean and standard error of three biological replicates. * Indicates significant 
difference compared to DMSO-vehicle controls, by Student’s t-test, where P < 
0.05. 
 
No significant fold enrichment of the cPLA2α promoter region was 
observed upon immunoprecipitation with the anti-H3K9ac antibody after TSA 
treatment, compared to DMSO-treated controls (Fig. 1.3.5.3 A). However, a 
significant 2.7-fold increase in fold enrichment of the cPLA2α promoter region 
was observed upon immunoprecipitation with the anti-H3K4me3 antibody, 






























1.3.6  Detection of H3K9 acetylation  
  
Fig. 1.3.6 Percentage of acetylated H3K9 residues detected in cells, 
compared to untreated controls. Data represent the mean and standard 
error of four biological replicates. Statistical significance analysed by Student’s 
t-test. 
 
No significant change in percentage acetylation of H3K9 was detected 
after TSA treatment (Fig. 1.3.6). 
 
1.3.7 Lactate dehydrogenase assay 






























































   
 
   
 
Fig. 1.3.7 Measurement of lactate dehydrogenase (LDH) activity. (A) 
Effect of anacardic acid (AA) and TSA on LDH release. (B) Effect of MTA and 
TSA on LDH release. (C) Effect of AACOCF3 and TSA on LDH release. 
Analysed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc 
test. * Indicates significant difference compared to the vehicle-treated group, 
*** P < 0.001. # Indicates significant difference compared to cells treated with 
0.5 µM TSA, ### P < 0.001. 
 
 
Significant increase in cytotoxicity by 5.8-fold was observed after 0.5 
µM TSA treatment (P < 0.001). Co-treatment of 20 µM anacardic acid with 0.5 
µM TSA caused a decrease in cytotoxicity by 36.8%, compared to cells 
























































with 0.5 µM TSA exacerbated cytotoxicity, compared to cells treated with TSA 
only (Fig. 1.3.7 B). Co-treatment of 20 µM AACOCF3 with 0.5 µM TSA 
significantly abrogated cell death and increased cell viability by 60%, 
compared to cells treated with TSA only (p < 0.001) (Fig. 1.3.7 C). 
 
1.4 Discussion 
The present study was performed to examine the epigenetic regulation 
of cPLA2 in SH-SY5Y human neuroblastoma cells. An initial screening was 
performed to elucidate the effects of TSA, a general HDAC inhibitor of class I, 
IIa, IIb and IV HDACs (Chuang et al., 2009), on mRNA expression of PLA2 
isoforms. Results showed dose-dependent upregulation of cPLA2α and 
iPLA2β isoforms after TSA treatment, but to a much larger extent for cPLA2α 
compared to iPLA2ß. This is consistent with current knowledge that TSA alters 
the expression of only ~2% of genes (Van Lint et al., 1996). In view of the 
large increases in cPLA2α mRNA expression after TSA treatment, we 
investigated the effects of more specific HDAC inhibitors on cPLA2α 
expression. Different classes of HDACs include class I, II and IV zinc-
dependent enzymes and class III zinc-independent enzymes, classified based 
on their homology to yeast HDACs and organization of protein domains (de 
Ruijter et al., 2003, Chuang et al., 2009). Class I HDACs comprise HDAC1, 2, 
3, and 8, due to their homology to yeast RPD3 HDACs (Chuang et al., 2009, 
Delcuve et al., 2012b). Class II HDACs are related to yeast HDA1 HDACs and 
are sub-divided into class IIa and class IIb (Chuang et al., 2009, Delcuve et 





HDAC6 and 10 (Chuang et al., 2009, Delcuve et al., 2012b). Class I HDACs 
are nuclear enzymes mainly involved in cell proliferation and survival (Luo et 
al., 2009, Marks, 2010). In our study, we used the class I and IIa HDAC 
inhibitor, VPA (Gurvich et al., 2004), the HDAC6-specific inhibitor, tubacin 
(Haggarty et al., 2003) and the class I HDAC inhibitor, MS-275 (Khan et al., 
2008, Kennedy et al., 2013, Beharry et al., 2014). As with TSA, treatment with 
all three inhibitors resulted in dose-dependent cPLA2α mRNA upregulation. 
However, VPA treatment induced iPLA2ß mRNA downregulation, possibly 
because VPA downregulates sterol regulatory element binding protein 
(SREBP) that in turn reduces iPLA2ß expression (Lagace and Nachtigal, 
2004). Tubacin induced small increases in both cPLA2α and iPLA2ß 
expression, indicating that HDAC6 plays a relatively small role in cPLA2α and 
iPLA2ß expression. MS-275 induced the largest increase in cPLA2α 
expression, suggesting that class I HDACs play the most significant role in 
epigenetic regulation of cPLA2α. In contrast, no changes were found in iPLA2ß 
expression after MS-275 treatment. Results show that cPLA2α but not iPLA2ß 
is differentially affected by class I HDACs.  
We next explored the role of HAT inhibitors in regulation of cPLA2. 
Treatment with the general HAT inhibitor anacardic acid and the p300-specific 
HAT inhibitor CCM by itself at several doses did not induce changes in 
cPLA2α and iPLA2ß mRNA expression. In contrast, co-treatment of cells with 
anacardic acid and TSA significantly reduced upregulation of cPLA2α induced 
by TSA. The mRNA changes were reflected at the protein level as shown by 





observed after TSA treatment, but was suppressed in cells that were co-
treated with anacardic acid and TSA. This suggests that HAT-activating 
processes are involved in TSA-induced cPLA2α expression. Anacardic acid is 
a general inhibitor of 3 classes of HATs, namely, p300/CBP, GCN5/PCAF and 
Tip60/MYST (Roth et al., 2001, Balasubramanyam et al., 2003, Sun et al., 
2006b, Cui et al., 2008). These 3 classes of HATs are classified based on 
sequence homology, protein structure and substrate specificity (Kuo and Allis, 
1998). We next sought to investigate which HAT was selectively involved in 
regulation of cPLA2α expression. Treatment of cells with CCM, a natural p300 
HAT inhibitor (Marcu et al., 2006); C646, the pharmacological p300 inhibitor 
(Santer et al., 2011); and MB-3, the GCN5 inhibitor (Biel et al., 2004), did not 
suppress cPLA2α upregulation induced by TSA. This suggests that the 
p300/CBP and GCN5/PCAF classes of HATs were minimally or not involved 
in the suppression of cPLA2α upregulation. In contrast, treatment of cells with 
the Tip60-specific HAT inhibitor NU9056 (Coffey et al., 2012) led to significant 
reduction of TSA-induced upregulation of cPLA2α mRNA expression, 
suggesting the role of Tip60 in cPLA2α expression.  
We further elucidated that NU9056 inhibited MS-275-induced 
upregulation of cPLA2α mRNA, indicating that the class I HDACs and the 
Tip60 HAT are specific enzymes involved in epigenetic regulation of cPLA2. 
HDAC inhibitors TSA and MS-275 induce acetylation of H3K9, H3K14, and 
trimethylation of H3K4 (Sike et al., Martinez-Diaz et al., 2010, Huang et al., 
2011, Coffey et al., 2012, Kennedy et al., 2013) (Table I). The inhibition of the 





reduction in acetylation levels of H3K14, H4K8 and H4K16 (Coffey et al., 
2012) (Table I). Therefore, one possibility by which MS-275 increase cPLA2α 
mRNA expression may be via increased acetylation of H3K14, which is in turn 
suppressed by NU9056, resulting in reduced cPLA2α expression. Western 
blots showed increased cPLA2 protein expression after MS-275 treatment, 
and that co-treatment with the Tip60 HAT inhibitor, NU9056, reduced the 
increase. Immunocytochemistry also showed increased cPLA2 
immunofluorescence after MS-275 treatment, which was suppressed in cells 
that were co-treated with NU9056 and MS-275. Since Tip60 HAT inhibition 
suppresses cPLA2 expression, it could imply that Tip60 has the potential to 
increase cPLA2α expression at the transcriptional level. Our findings add to 
previous studies, which showed that a splice variant of Tip60, cPLA2-
interacting protein (PLIP) can interact with cPLA2 at the protein level to induce 
apoptosis (Sheridan et al., 2001).  
Although TSA is widely known to increase H3K9 acetylation, it is also 
known to induce trimethylation of H3K4 to cause transcriptional activation of 
genes (Nightingale et al., 2007, Pufahl et al., 2012, Wu et al., 2012b, a). Since 
trimethylated H3K4 is often associated with acetylated H3K9 histones in 
activated genes (Nightingale et al., 2007), we investigated the possibility of 
increased H3K4 trimethylation after TSA treatment. The histone 
methyltransferase (HMT) inhibitor MTA was used to investigate the effect of 
H3K4-trimethylation inhibition on TSA-induced cPLA2α expression, since it 
effectively reduces trimethylation of H3K4 (Huang et al., 2006, El Mansouri et 





reduced TSA-induced increase in cPLA2α expression. Western blots showed 
that TSA treatment increased cPLA2 protein expression, and this increase 
was modulated by the HMT inhibitor, MTA. Immunocytochemistry also 
showed increased cPLA2 immunofluorescence after TSA treatment, which 
was suppressed in the cells that were co-treated with MTA and TSA. 
Together, results indicate that cPLA2 can be regulated by histone methylation 
as well as histone acetylation. 
We next explored the site on the cPLA2α promoter, in which the above 
epigenetic changes might occur by chromatin immunoprecipitation (ChIP). 
Sheared DNA obtained from lyzed SH-SY5Y cells showed a smear ranging 
from 200-800 base pairs, compared to unsheared controls, indicating 
successful sonication of samples for downstream immuoprecipitation. ChIP- 
sequencing data obtained from the Human Epigenome Atlas on cell types 
most similar to SH-SY5Y cells showed no distinct genetic loci rich in H3K9ac 
on the cPLA2α gene. In contrast, ChIP-sequencing data of H3K4me3 
suggested a distinct site rich in H3K4me3 near the transcriptional start site of 
cPLA2α, leading us to postulate that this site could be an area of active 
transcriptional activity. ChIP-qPCR showed absence of significant enrichment 
of the cPLA2α promoter region after immunoprecipitation with anti-H3K9ac 
antibody. H3K9 acetylation assay results also showed no change in H3K9ac 
levels after TSA treatment. These results indicate that TSA does not increase 
cPLA2α  expression via acetylation of H3K9. In contrast, ChIP – qPCR 
confirmed significant enrichment of the cPLA2α promoter region in TSA-





findings are consistent with our observations that the HMT inhibitor MTA 
significantly suppresses TSA-induced cPLA2α mRNA expression. Together, 
results suggest that TSA increases binding of H3K4me3 at this specific gene 
region (+143 to +349) to facilitate transcription of cPLA2α.  
Subsequently, we investigated the role of epigenetic regulation on cell 
viability of SH-SY5Y cells. The neuroprotective potential of anacardic acid and 
MTA were first explored, followed by elucidation of the role of cPLA2 in TSA-
induced cell death using the specific enzymatic inhibitor, AACOCF3. Recent 
studies highlight TSA as a potential drug candidate in the treatment of cancer 
(Mariadason et al., 2000), and TSA has been shown to inhibit cell viability in 
SH-SY5Y cells and neuron-like cells (Wang et al., 2009). In our study, 
treatment of cells with TSA increased LDH release into the culture media, 
indicating cellular injury. Conversely, treatment with anacardic acid led to 
significant abrogation of cytotoxicity, indicating a potentially neuroprotective 
role of anacardic acid. This is consistent with previous studies showing that 
anacardic acid protected against H3 and H4 histone acetylation and 
dopaminergic neuronal apoptosis in primary mesencephalic neurons (Song et 
al., 2010). The HMT inhibitor MTA did not protect against TSA-induced cell 
death. The reason for this is unknown, but possibly due to other genes that 
are activated by HMTs, such as inhibition of methylation of lamin B that 
causes solubilization of lamins and subsequent induction of apoptosis (Lee 
and Cho, 1998). We also sought to determine a possible role of cPLA2 in 
TSA-induced cell death. LDH release indicating cellular injury was significantly 





a contributor to TSA-induced cell death. Thus, reported anti-cancer effects of 
TSA (Mariadason et al., 2000) may involve cPLA2-related mechanisms. This 
could occur through release of arachidonic acid, which may be metabolised to 
generate free radicals and proinflammatory eicosanoids that induce cell death 
(Scorrano et al., 2001, Pompeia et al., 2003, Ong et al., 2010). AACOCF3 was 
used for the selective inhibition of cPLA2 enzyme activity, since it is known to 
be 500-fold more potent in blocking cPLA2 activity at 15 µM as compared to 
iPLA2 and sPLA2 (Trimble et al., 1993, Liu et al., 2014). As a further 
confirmation, future studies can include the use of additional PLA2 inhibitors or 
the specific inhibition of cPLA2 using siRNA (Morris et al., 2004). 
Epigenetic regulation of inflammatory genes have been proposed to 
give rise to chronic inflammation (Wilson, 2008). General decreases in HDAC 
activities have been reported in patients with chronic obstructive pulmonary 
disease (Mroz et al., 2007) and inflammatory lung disease treatments with 
corticosteroids and theophylline have been found to interfere with HAT and 
HDAC activities to downregulate inflammatory genes (Barnes et al., 2005). 
Increased HAT activity and decreased HDAC activity have also been 
implicated in asthma cases (Kuo et al., 2014). In the CNS, late-onset AD in 
humans are characterized by a phenomenon known as “age-specific 
epigenetic drift”, where epigenetic signatures in the genome change over 
time, leading to changes in gene expression, pathology and behavior (Wang 
et al., 2008). Our findings provide novel evidence for epigenetic regulation in 
cPLA2 expression in a neuron-like cell line, and may point to similar effects in 





Nutrients and bioactive food components have also been proposed to 
induce epigenetic modifications and alter gene expression over time (Choi 
and Friso, 2010). In our study, we noted that the well-known HAT inhibitor 
anacardic acid, a flavonoid extract derived from cashew nuts, suppressed 
TSA-induced cPLA2 expression. A search for South-East Asian plants with 
similar properties revealed that Clinacanthus nutans Lindau (Sabah Snake 
Grass) leaf extracts also suppressed TSA-induced cPLA2 upregulation and 
cellular injury, similar to anacardic acid (Tan et al., unpublished data). Results 
suggest potential for phytochemicals to have significant effects on chronic 














EFFECTS OF CLINACANTHUS NUTANS ON 







Clinacanthus nutans Lindau (C. nutans) belongs to the family 
Acanthaceae and the genus Clinacanthus, along with its closely associated 
species, Clinacanthus siamensis Brem (Smitinand, 1980). C. nutans was 
traditionally used for treatment of snake bites (Daduang et al., 2005), insect 
bites and herpes infections in Thailand (Sakdarat et al., 2006, Uawonggul et 
al., 2006). Commonly referred to as ‘Sabah Snake Grass’, it is now a 
recognised medicinal plant with anti-inflammatory and analgesic properties 
(Pongphasuk and Khunkitti, 1996). C. nutans extracts significantly inhibit 
carrageenan-induced paw edema in mice and rats as well as ethyl 
phenylpropiolate-induced ear edema in rats via suppression of neutrophil 
migration (Pongphasuk and Khunkitti, 1996, Wanikiat et al., 2008). It has 
antiviral effects against the herpes simplex virus type-2 (Wirotesangthong and 
Rattanakiat, 2006, Kunsorn et al., 2013), and possess antioxidant and 
anticancer effects on cultured human cancer cell lines (Yong et al., 2013). 
The ethanol extract of C. nutans leaves comprise a mixture of nine 
cerebrosides and a monoacylmonogalactosylglycerol, as established by 
spectroscopic and chemical reactions (Tuntiwachwuttikul et al., 2004). The 
chloroform extract isolated after chromatographic separation comprise three 
chlorophyll derivatives (phaeophytins) related to chlorophyll a and chlorophyll 
b, and possesses anti-herpes simplex virus activity (Sakdarat et al., 2006). 
The active components, namely, lupeol, vitexin, orientin and cerebrosides, 





edema (Saleem, 2009, Loizou et al., 2010, Borghi et al., 2013, Mandal et al., 
2014, Zhou et al., 2014).  
Cytosolic phospholipase A2 (cPLA2) is a key enzyme implicated in 
chronic inflammatory neurodegeneration due to ischemia or excitotoxicity 
(Lukiw and Bazan, 2000, Bazan et al., 2002, Sun et al., 2012). It regulates the 
production of second messengers such as arachidonic acid and PAF in brain 
tissues (Farooqui et al., 1997). Arachidonic acid produces proinflammatory 
eicosanoids and plays a major role in signaling and inflammatory modulation 
in the brain (Farooqui et al., 1997).  
 Our previous findings (Chapter 1) elucidated that HDAC inhibition by 
TSA and MS-275 led to large increases in cPLA2α expression, which were 
suppressed by HAT inhibitors, anacardic acid and NU9056. Anacardic acid is 
a well-known flavonoid extract derived from cashew nuts, and is a 
nutraceutical among several others that also possess HAT inhibitory 
properties (Sung et al., 2008, Ghizzoni et al., 2011). For instance, plumbagin, 
a compound derived from the medicinal plant Plumbago zeylanica, inhibits the 
p300/CBP HAT and downregulates NF-kB-dependent gene expression 
(Sandur et al., 2006, Ravindra et al., 2009). Curcumin, a component of 
Curcuma longa, commonly known as turmeric, is also an inhibitor of 
p300/CBP HAT that suppresses TNFα-induced p65 acetylation, which in turn 
downregulates NF-kB-dependent expression of many inflammatory genes 
(Balasubramanyam et al., 2004). Garcinol, a polyisoprenylated benzophenone 
derivative from Garcinia indica fruit, possess p300/CBP HAT inhibitory 





anti-cytotoxic effects by generating neurotrophic factors essential for cell 
viability (Blaylock and Maroon, 2012). In this part of the study, we investigated 
the anti-inflammatory effects of C. nutans via cPLA2 regulation in SH-SY5Y 
human neuroblastoma cells, and explored its potential mechanism of function 
via epigenetic means. Last but not least, the role of C. nutans in modulation of 
cell viability was investigated.  
 
2.2 Materials and Methods 
2.2.1 Plant materials and plant extracts 
 Clinacanthus nutans extracts were derived from the whole plant 
commonly known as Sabah Snake grass. It was provided by A/P Ong Wei Yi, 
and extracted with the kind assistance of A/P Benny Tan and Annie Hsu 
(Department of Pharmacology, National University of Singapore). The leaves 
(778.65 g) were rinsed with distilled water and soaked in 80% denatured 
ethanol. The leaves were homogenized (Wiggen Hauser D-500) and the 
mixture left to stand for one hour. The ethanol extract was then filtered under 
vacuum (Gast USA DOA-PIO4-BN) with 90 mm glass microfiber filter 
membranes (Whatman, Little Chalfont, Buckinghamshire, UK). The filtrate 
was concentrated in a rotary evaporator at 50°C (Buchi Labortechnik AG, 
Postfach, Switzerland). The resultant dark green condensate was subject to 
freeze-drying (Christ Gamma 1-16 LSC) for 1–2 days. After drying, 
appearance of the solid residue obtained (27.02 g) was a dark green powder. 
The extract yield (w/w) from 778.65 g of fresh leaves was approximately 









Treatments administered to SH-SY5Y cells were DMSO, TSA and C. 
nutans. DMSO and TSA were purchased from Sigma (St. Louis, MO). The C. 
nutans extracts were weighed and dissolved in DMSO before treatment.  
 
2.2.3 Cell culture 
 SH-SY5Y human neuroblastoma cells were obtained from ATCC 
(Manassas, VA) and cultured in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin (Gibco-Invitrogen, Carlsbad, CA). Cells were grown in 
100 mm2 cell culure dishes and incubated in 37ºC, 100% humidity with 95% 
air and 5% CO2, as previously described. 
 
2.2.4 Treatment with C. nutans and general HDAC inhibitor, TSA 
To study the effects of C. nutans and the general HDAC inhibitor TSA 
on cPLA2 expression, SH-SY5Y cells were divided into four groups and 
treated as follows: (1) DMSO as vehicle control, (2) 0.5 µM TSA, (3) 100 µg/ml 
C. nutans, (4) 100 µg/ml C. nutans and 0.5 µM TSA. TSA was administered at 
the IC50 dose of 0.5 µM (Muhlethaler-Mottet et al., 2008). C. nutans was 
administered at a dose of 100 µg/ml, a dose known to exert a physiological 
effect in cells (Wanikiat et al., 2008, Yong et al., 2013). Cells were co-





2.2.5 Real-time quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) 
 Total RNA extraction from SH-SY5Y cells was performed with the 
RNeasy Mini kit (Qiagen, Hamburg, Germany). Reverse transcription of RNA 
to cDNA was performed using the High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA), as described previously. Real-time 
RT-PCR was then carried out using the TaqMan® Universal PCR Master Mix 
(Applied Biosystems, Foster City, CA) with specific TaqMan® Gene 
Expression Assay Probes for cPLA2α (Hs00233352_m1), and β-actin 
(#4326315E) (Applied Biosystems, Foster City, CA). The qRT-PCR was run 
on the Applied Biosystem 7500 Real-Time PCR system (Applied Biosystems, 
Foster City, CA), as described previously. The relative amount of gene 
transcript was estimated after normalization to the endogenous control gene, 
β-actin. Using the 2-ΔΔCT method as previously described (Livak and 
Schmittgen, 2001), the relative fold changes were quantified. All reactions 
were performed in triplicates and the mean and standard error calculated. 
Statistical differences were analysed using one-way ANOVA with Bonferroni’s 
multiple comparison post-hoc test, where P < 0.05 was deemed significant. 
 
2.2.6 HAT activity assay 
 In vitro acetylation assay was performed with the Fluorescent HAT 
Assay kit, according to the manufacturer’s protocol (Active Motif, La Hulpe, 
Belgium). Test reagents were added in triplicates into a 96-well flat white plate 





domain (0.1 mg/ml) was used as a HAT source and was incubated with 
acetyl-CoA and specific synthetic H3 and H4 substrate peptides (provided in 
kit). The. To exclude a possible disturbance by autoacetylation or 
autofluorescence of C. nutans in these assays, an additional background 
control was performed. 15 µM anacardic acid was used as a positive control 
for HAT inhibition. The plate was read at an excitation wavelength of 360 nm 
and an emission wavelength of 450 nm on the Tecan Infinite® 200 microplate 
reader (Tecan Group Ltd., Maennedorf, Switzerland). Average arbitrary 
fluorescence units (AFU) readings from the triplicate wells were obtained. All 
reactions were performed in triplicates and the mean and standard error 
calculated. Statistical differences were analysed using one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test, where P < 0.05 was deemed 
significant. 
 
2.2.7 Detection of H3K9 acetylation levels 
 Detection of H3K9 acetylation was performed using the EpiQuikTM In 
Situ Histone H3-K9 Acetylation Assay Kit (# P-4004, Epigentek, Farmingdale, 
NY). Cells were cultured in a 96-well microplate (provided in kit) and grown to 
80% confluency. They were divided into six treatment groups (1) DMSO 
vehicle control, (2) 0.5 µM TSA, (3) 50 µg/ml C. nutans, (4) 50 µg/ml C. 
nutans and 0.5 µM TSA, (5) 100 µg/ml C. nutans, (6) 100 µg/ml C. nutans and 
0.5 µM TSA. Each group consisted of four biological replicates. After 
treatment, cells were incubated overnight for 24 hours before performance of 





Tecan Infinite® 200 microplate reader (Tecan Group Ltd., Maennedorf, 
Switzerland) at 450 nm within 10 minutes, and the % H3K9 acetylation was 
calculated according to the following formula: 
Acetylation %  =   O. D. (treated sample-blank)O.D. (untreated control-blank)  x 100 
The average values were then normalised against untreated controls. The 
mean and standard errors were calculated, and significant differences were 
analysed using one-way ANOVA with Bonferroni’s multiple comparison post-
hoc test, where P < 0.05 was deemed significant.  
 
2.2.8 Immunocytochemistry 
 SH-SY5Y cells were counted and 2 x 105 cells were cultured on poly-L-
lysine-coated coverslips placed in 24-well plates. They were grown to 80% 
confluency before administration of treatment. SH-SY5Y cells were divided 
into four groups and treated as follows: (1) DMSO as vehicle control, (2) 0.5 
µM TSA, (3) 100 µg/ml C. nutans, (4) 100 µg/ml C. nutans and 0.5 µM TSA. 
After 24 hours, the LDH assay was performed as previously described, using 
the rabbit polyclonal cPLA2 antibody (sc-438, 1:50 in 3% BSA, Santa Cruz 
Biotechnology, Santa Cruz, CA), followed by secondary incubation with the 
anti-rabbit Alexa Fluor 488 (Applied Biosystems, Foster City, CA; diluted 
1:200). Nuclei were labelled and coverslips mounted with the Prolong Gold 
Anti-fade Mountant DAPI (Invitrogen, Carlsbad, CA). After drying overnight, 
the samples were analysed and images captured using the confocal 






2.2.9 Quantitative image analysis 
To measure the fluorescence intensity of cells between the treatment  
groups, images were captured using the confocal microscope (Zeiss, Jena, 
Germany) at the plane with the best focus. An average of ten to fifteen images 
were captured per treatment group. The region around each cell was 
demarcated and measured with the Image J software (Burgess et al., 2010, 
Gavet and Pines, 2012). Background readings were obtained by obtaining 
values of at least three regions of background fluorescence. The net 
fluorescent intensity was calculated for each image according to the following 
formula: Corrected total cell fluoresence (CTCF) = Integrated Density – (Area 
of selected cell x Mean fluorescence of background readings). The net 
average intensity values were then normalised against vehicle-treated 
controls. The mean and standard error were calculated and significant 
differences analysed using one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test, where P < 0.05 was deemed significant. 
 
2.2.10 Trypan blue exclusion and cell viability assay 
 SH-SY5Y cells were grown on 100 mm2 tissue culture dishes and 
grown to 80% confluency. SH-SY5Y cells were divided into four groups and 
treated as follows: (1) DMSO as vehicle control, (2) 0.5 µM TSA, (3) 100 µg/ml 
C. nutans, (4) 100 µg/ml C. nutans and 0.5 µM TSA. After 24 hours, cells 
were harvested and exposed to trypan blue for five minutes, before 
percentage cell viability was determined. Values were normalised against 





significance differences were analysed using one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test, where P < 0.05 was deemed 
significant. 
 
2.2.11 Lactate dehydrogenase assay 
 SH-SY5Y cells were counted and 2 x 105 were cultured in 24-well 
plates. They were grown to 80% confluency before administration of 
treatment. The cells were divided into four groups for administration of 
treatment as follows: (1) DMSO as vehicle control, (2) 0.5 µM TSA, (3) 100 
µg/ml C. nutans, (4) 100 µg/ml C. nutans and 0.5 µM TSA. Cell viability was 
accessed after 24 hours by colorimetric determination of LDH release, using 
the LDH Cytotoxicity Detection Kit (Roche, Mannheim, Germany), according 
to manufacturer’s protocol. Percentage of cell death was calculated and the 
average of three plate readings taken. The plate was read at an excitation 
wavelength of 490 nm on the Tecan Infinite® 200 microplate reader (Tecan 
Group Ltd., Maennedorf, Switzerland). The reference absorbance reading was 
subtracted from the absorbance at 490 nm. Percentage cytotoxicity was 
calculated according to the formula: 
Cytotoxicity   % =experimental value-low controlhigh control-low control  × 100  
The mean cytotoxicity values were then normalised against vehicle-treated 
controls. The mean and standard errors were calculated, and significant 
differences analysed using one-way ANOVA with Bonferroni’s multiple 






2.3.1 Effect of C. nutans and TSA on cPLA2α mRNA expression 
 
Figure 2.3.1 Real-time RT-PCR analyses of cPLA2α mRNA expression 
after treatment with C. nutans and general HDAC inhibitor, TSA. Data 
represent mean and standard error of four biological replicates. Statistical 
analysis by one-way ANOVA with Bonferroni’s multiple comparison post-hoc 
test. * Indicates significant difference compared to DMSO-treated vehicle 
controls, *** P < 0.001. # Indicates significant difference compared to cells 
treated with 0.5 μM TSA, # P < 0.05. 
 
A significant 1554-fold increase in cPLA2α mRNA expression was 
observed after treatment with 0.5 µM TSA, compard to DMSO-treated vehicle 
controls (P < 0.001) (Fig. 2.3.1 A). Co-treatment of 100 µg/ml C. nutans with 
0.5 µM TSA significally reduced the effect of TSA treatment on cPLA2α mRNA 
expression by 36.2%, compared to cells treated with TSA only (P = 0.041) 
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2.3.2 HAT activity assay 
 
Fig. 2.3.2 Histone acetyltransferase (HAT) activity assay results showing 
HAT activity in arbitrary fluorescence units (AFU). Analysed by one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc test. Data represent 
the mean and standard error of four biological replicates. * Indicates 
significant difference compared background flurescence levels, *** P < 0.001. 
# Indicates significant difference compard to p300 positive control for HAT 
activity. ## P < 0.01, ### P < 0.001. 
 
Background level of fluorescence indicated fluorescence reading of 
22700 AFU (P < 0.001). Positive control for HAT inhibition, anacardic acid, 
showed similarly low fluorescence reading of 23600 AFU (P = 0.001). 
Significant increase in fluorescence reading of 41300 AFU was detected in the 
positive control for HAT activity, p300 HAT, compared to background controls 
(P < 0.001). Significant decrease in fluorescence reading of 27700 AFU was 





































2.3.3 Detection of H3K9 acetylation 
 
Fig. 2.3.3 Percentage of acetylated H3K9 residues detected in cells, 
compared to untreated controls. Analysed by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. Data represent the mean and 
standard error of four biological replicates. 
 
No significant change in percentage acetylation of H3K9 was detected 
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Figure 2.3.4 Effect of C. nutans and general HDAC inhibitor, TSA 
treatment on cPLA2 protein expression. (A) Immunocytochemistry photos 
of cPLA2 protein expression in SH-SY5Y cells after C. nutans and TSA 
treatment. (B) Quantification of ten high-power microscopic fields from four 
biological replicates per group analysed and computed as average corrected 
total cell fluorescence (CTCF) values. Scale bar = 20 µm. AFU: arbitrary 
fluorescence units. Data represent mean and standard error of four biological 
replicates. Analysed by one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. * Indicates significant difference compared to 
DMSO-treated vehicle controls, *** P < 0.001. # indicates significant difference 
compared to cells treated with 0.5 μM TSA, ### P < 0.001. 
 
Significant increase in fluorescence intensity was detected after 
treatment with 0.5 µM TSA, with an average fluorescence value of (1.1 x 105 
AFU), as compared to cells in the DMSO-treated vehicle control group with 
average fluorescence value of (3.4 x 104 AFU) (P = 0.012). Fluorescence 
intensity remained low (4.4 x 104 AFU) after treatment with C. nutans alone. 
Co-treatment of 100 µg/ml C. nutans with 0.5 µM TSA resulted in a 
significantly lowered average fluorescence value of (4.3 x 104 AFU), compared 





2.3.5 Trypan blue exclusion and cell viability assay 
 
Fig 2.3.5 Trypan blue exclusion assay results. Measurement of cell 
viability after treatment with C. nutans and TSA. Data represent mean and 
standard error of six biological replicates, analysed by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. * Indicates significant 
difference compared with DMSO-treated control group, * P < 0.05. # Indicates 
significant difference compared to cells treated with 0.5 μM TSA, # P < 0.05 
 
 Significant drop in cell viability was observed after TSA treatment (P = 
0.002). C. nutans treatment alone did not decrease cell viability, while co-
treatment of 100 µg/ml C. nutans with 0.5 µM TSA significantly suppressed 
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2.3.6 Lactate dehydrogenase assay 
 
Fig. 2.3.6 Lactate dehydrogenase (LDH) assay results. Measurement of 
percentage LDH release after treatment with TSA and C. nutans. Data 
represent mean and standard error of four biological replicates, analysed by 
one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. * 
Indicates significant difference compared with DMSO-treated control group, 
*** P < 0.001. # Indicates significant difference compared to cells treated with 
0.5 μM TSA, ### P < 0.001 
 
Significant increase in cytotoxicity by 5.8-fold was observed after 0.5 
µM TSA treatment (P < 0.001). Co-treatment of 100 µg/ml C. nutans with 0.5 
µM TSA brought about significant reduction in cytotoxicity by 1.5-fold (39.2%) 
(P < 0.001), compared to cells treated with TSA only (Fig. 2.3.6).  
 
2.4 Discussion 
 C. nutans is a species of medicinal plants used in Thai traditional 
medicine, belonging to the family Acanthaceae (Tiangburanatam, 1996). In 
the first part of our study (Chapter 1), we showed that the general HDAC 
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indicating an important role of HDAC inhibition in the regulation of cPLA2 in 
SH-SY5Y cells. We also found that co-treatment of cells with the general HAT 
inhibitor anacardic acid and TSA modulated upregulation of cPLA2α induced 
by TSA. These changes were found to corroborate with protein expression as 
shown by Western blots and immunocytochemistry. Cell injury observed after 
TSA treatment was partially abrogated by anacardic acid. The role of cPLA2 in 
modulating TSA-induced injury was shown after co-incubation with the cPLA2 
selective inhibitor, AACOCF3, indicating the involvement of cPLA2 in TSA-
induced cell injury. In view of the positive effects of the natural compound, 
anacardic acid, on cPLA2 expression, this part of the study was performed to 
investigate the effects of C. nutans and TSA on cPLA2 expression, and 
thereafter to investigate its mechanism of action and possible cytoprotective 
effects. 
 In line with our previous findings, the general HDAC inhibitor TSA 
induced significant upregulation of cPLA2α mRNA expression. Co-treatment of 
cells with C. nutans and TSA significantly reduced expression of cPLA2α 
induced by TSA. This suppression of cPLA2α mRNA expression by C. nutans 
highlights its anti-inflammatory potential, similar to the general HAT inhibitor 
anacardic acid and Tip60-specific HAT inhibitor NU9056, which significantly 
suppressed TSA-induced cPLA2α upregulation (Chapter 1).  
 In view of the fact that many nutraceuticals have HAT inhibitory 
properties (Sung et al., 2008, Choi and Friso, 2010), we hypothesized that C. 
nutans may possess HAT inhibitory properties similar to that of the general 





HAT activity assay showed significantly lowered fluorescence reading 
produced by C. nutans extracts, compared to the p300 HAT control, indicating 
the presence of significant inhibition of p300 HAT activity by C. nutans. 
Results indicate that C. nutans regulate cPLA2α expression at least in part via 
p300 HAT inhibition. 
 We next explored the effects of C. nutans and TSA on the acetylation 
status of Lys-9 of histone H3 (H3K9) because it is a known substrate of the 
p300 HAT (Yuan et al., 2013) and is typically associated with activated genes 
(Karmodiya et al., 2012). H3K9 acetylation assay results showed no 
significant change in H3K9ac levels after TSA and C. nutans treatment. This 
supports our previous ChIP-qPCR findings showing absence of significant 
enrichment of the cPLA2α promoter region after immunoprecipitation with anti-
H3K9ac antibody (Chapter 1). Together, findings suggest that TSA does not 
increase cPLA2α expression via acetylation of H3K9. Our findings add to 
previous studies on mouse embryos, which showed that the positive effect of 
TSA on the development of the embryo was not attributed to modifications in 
acetylation levels of H3K9 (Li et al., 2015). C. nutans might regulate cPLA2α 
expression via altering acetylation statuses of other histone residues besides 
H3K9. Since TSA induces acetylation of H3K9, H3K14, and trimethylation of 
H3K4 (Sike et al., Martinez-Diaz et al., 2010, Huang et al., 2011, Coffey et al., 
2012, Kennedy et al., 2013) (Table I), TSA might increase cPLA2α mRNA 
expression by increasing acetylation of H3K14, which is in turn reduced by the 
HAT inhibitory effects of C. nutans. 





blots showed increased cPLA2 protein expression after TSA treatment, and 
co-treatment with C. nutans reduced the increase. Immunocytochemistry also 
showed increased cPLA2 immunofluorescence after TSA treatment, which 
was suppressed in cells that were co-treated with C. nutans and TSA. Results 
indicate that leaf extracts of C. nutans possess anti-inflammatory effects, and 
point to potential anti-inflammatory effects in distinct constituents of C. nutans. 
We previously showed that cell injury observed after TSA treatment 
was abrogated by co-treatment with cPLA2 selective inhibitor AACOCF3, 
indicating that TSA induces cell injury via cPLA2-related mechanisms (Chapter 
1). We also showed presence of cytoprotective effects by anacardic acid 
where significant abrogation of cytotoxicity was detected after co-treatment of 
cells with anacardic acid and TSA (Chapter 1). Here, we further explored the 
cytoprotective potential of C. nutans in TSA-induced cell injury. Significant 
decrease in the number of trypan blue negative cells were observed after TSA 
treatment compared to DMSO-treated vehicle controls, showing that TSA 
reduced cell viability. Co-treatment of cells with C. nutans and TSA led to a 
significant increase in number of trypan blue negative cells compared to cells 
treated with TSA alone, indicating that C. nutans modulated the cell injury 
induced by TSA. The cytoprotective nature of C. nutans was confirmed using 
the LDH assay. As observed previously, treatment of cells with TSA increased 
LDH release into the culture media, indicating cellular injury. Co-treatment of 
cells with C. nutans and TSA significantly reduced LDH release, pointing to 
significant abrogation of cytotoxicity. Together, results from both assays 





 The suppression of cPLA2α mRNA upregulation by C. nutans indicates 
presence of anti-inflammatory properties in C. nutans and possibly in distinct 
constituents within the leaf extracts. The constituents of C. nutans have been 
phytochemically and chemically studied (Sakdarat et al., 2009), and some of 
these such as lupeol (Saleem, 2009), β-sitosterol (Loizou et al., 2010), vitexin 
(Borghi et al., 2013), orientin (Zhou et al., 2014) and cerebrosides (Mandal et 
al., 2014) were previously shown to have anti-inflammatory properties. Lupeol 
is found in various other natural foods such as mangoes, grapes, white 
cabbage, strawberries, olives and green peppers (Saleem, 2009), and thus 
point to potential anti-inflammatory properties within these foods. A closely 
related species, Clinacanthus siemensis (C. siemensis), possess anti-
inflammatory properties (Sreena et al., 2012). Hygrophilaspinosa T. Anders, a 
species of the same family Acanthaceae, also show anti-inflammatory 
potential via alleviation of carrageenan-induced paw oedema in rats (Arjun et 
al., 2009). Therefore, our findings add to previous studies that show benefits 
of phytochemicals in natural plant products, and point to the potential for more 
phytochemicals in this family to be identified for the alleviation of chronic 
inflammation. 
 Besides inhibiting p300 HAT, C. nutans could likewise inhibit the Tip60 
HAT, since the Tip60 HAT was shown to play a significant role in cPLA2 
regulation (Chapter 1). C. nutans could also inhibit other substrates such as 
the transcription factor NF-kB, which is known to be affected by HATs and 
HDACs (Dai et al., 2005). One such example is triptolide, a diterpene 





which inhibits acetylation of the p65 subunit of NF-kB and suppresses its 
activation (Zhu et al., 2009, Park et al., 2011). In view of such functions in 
other phytochemicals such as triptolide, it is possible that C. nutans may 
likewise suppress cPLA2α expression via NF-kB inhibition. 
Taken together, it was observed that co-treatment of SH-SY5Y cells 
with C. nutans leaf extracts suppressed TSA-induced cPLA2 expression in a 
similar manner as known HAT inhibitors, and it possesses p300 HAT 
inhibitory properties. We also found that C. nutans also abrogated cytotoxicity 
induced by TSA. Therefore, results in this part of the study show anti-
inflammatory and cytoprotective effects of C. nutans. These findings provide 
hope for natural dietary strategies for therapy for chronic inflammation. The 
constituents of C. nutans can also serve as potential candidates for the 
development of new anti-inflammatory compounds that can alleviate 




















In conclusion, this study shows the presence of epigenetic regulation in 
cPLA2. In the first part of our study, we showed that the general HDAC 
inhibitor TSA induced significant upregulation in cPLA2α expression, indicating 
an important role of HDAC inhibition in the regulation of cPLA2 in SH-SY5Y 
cells. This was especially so for the class I HDAC specific inhibitor, MS-275, 
which induced the greatest increase in cPLA2α expression, suggesting that 
class I HDACs play the most significant role in epigenetic regulation of 
cPLA2α. We also found that co-treatment of the general HAT inhibitor 
anacardic acid with TSA modulated upregulation of cPLA2α induced by TSA. 
Specific involvement of class I HDACs and the Tip60 HAT in cPLA2α 
regulation was further shown, where the Tip60 HAT inhibitor, NU9056, 
significantly reduced the upregulation of cPLA2α induced by MS-275. These 
changes were found to corroborate with protein expression as shown by 
Western blots and immunocytochemistry. Co-treatment with the HMT inhibitor, 
MTA also suppressed TSA-induced cPLA2 upregulation, showing that cPLA2 
expression can be influenced by histone methylation as well. ChIP results 
show that TSA increases expression of the cPLA2α gene via increases in 
H3K4 trimethylation. Cell injury observed after TSA treatment was partially 
abrogated by anacardic acid, indicating presence of cytoprotective effects. 
The role of cPLA2 in modulating TSA-induced cell injury was elucidated by 
significant abrogation of cytotoxicity after co-incubation with the cPLA2 
selective inhibitor, AACOCF3. 
In the second part of the study, we showed that co-treatment of cells 





similar manner as anacardic acid, and presence of p300 HAT inhibitory 
properties was elucidated. C. nutans also abrogated cytotoxicity induced by 
TSA, pointing to the presence of anti-inflammatory as well as cytoprotective 
effects. 
Taken together, results in this study show presence of epigenetic 
regulation in cPLA2, and provides promising hope for the use of 
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